WO2018216659A1 - Emulsion composition - Google Patents
Emulsion composition Download PDFInfo
- Publication number
- WO2018216659A1 WO2018216659A1 PCT/JP2018/019511 JP2018019511W WO2018216659A1 WO 2018216659 A1 WO2018216659 A1 WO 2018216659A1 JP 2018019511 W JP2018019511 W JP 2018019511W WO 2018216659 A1 WO2018216659 A1 WO 2018216659A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oil
- component
- acid
- precipitates
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to an emulsified composition containing glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and / or salts thereof, and ufenamate, and suppressing the formation of precipitates and precipitates.
- Non-steroidal anti-inflammatory drugs have almost no serious side effects as seen with steroidal anti-inflammatory drugs, and there are few restrictions on the amount and period of use, so rash, redness, dry dermatitis, atopy It is also widely used in external preparations for the purpose of alleviating inflammatory skin diseases such as atopic dermatitis.
- glycyrrhetinic acid glycyrrhizic acid, derivatives thereof, and salts thereof (hereinafter sometimes referred to as “glycyrrhetinic acids”) have a tissue repair action in addition to an anti-inflammatory action. And is widely used in external preparations.
- glycyrrhetinic acids glycyrrhetinic acids
- ufenamate has the same anti-inflammatory effect as flufenamic acid and has lower local irritation than flufenamic acid, making it suitable for delicate skin applications and long-term use. It is widely used for external preparations.
- non-steroidal anti-inflammatory agents have a drawback that their anti-inflammatory action is slower than steroidal anti-inflammatory agents. Therefore, in recent years, in order to effectively exert an anti-inflammatory effect, an attempt has been made to combine two or more types of non-steroidal anti-inflammatory agents having different action mechanisms, and an external preparation using a combination of glycyrrhetinic acids and ufenamate. Has been developed.
- Patent Document 1 discloses that a gel ointment containing a poorly water-soluble active ingredient such as ufenamate, a nonionic surfactant, an auxiliary agent such as glycyrrhetinic acid, and water can stably hold the poorly water-soluble active ingredient.
- a poorly water-soluble active ingredient such as ufenamate
- a nonionic surfactant such as ufenamate
- an auxiliary agent such as glycyrrhetinic acid
- An object of the present invention is to provide an emulsified composition containing glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and / or their salts, and ufenamate, and suppressing the formation of precipitates and precipitates.
- the present inventor conducted intensive studies to solve the above-mentioned problems. As a result, in an emulsion composition containing glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and / or salts thereof, and ufenamate, diphenhydramine and / or its It discovered that the production
- Emulsifying composition containing at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, (B) ufenamate, and (C) diphenhydramine and / or a salt thereof. object.
- Item 2. The emulsified composition according to Item 1, containing a higher alcohol that is solid at 25 ° C.
- a method of suppressing phase separation between the water phase and the water phase (A) glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and at least one selected from the group consisting of these salts, and (B) ufenamate, (C) diphenhydramine and / or a salt thereof, and (D) 25 A method of blending a higher alcohol that is solid at °C.
- the emulsified composition of the present invention can suppress the formation of precipitates and precipitates by containing diphenhydramine and / or a salt thereof while containing glycyrrhetinic acids and ufenamate. Moreover, the emulsion composition of this invention can also suppress isolation
- Emulsified composition The emulsified composition of the present invention comprises at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof (hereinafter sometimes referred to as component (A)). And Ufenamate (hereinafter sometimes referred to as the component (B)) and diphenhydramine and / or a salt thereof (hereinafter sometimes referred to as the component (C)).
- component (A) glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof
- component (B) Ufenamate
- diphenhydramine and / or a salt thereof hereinafter sometimes referred to as the component (C)
- the emulsified composition of the present invention contains glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and / or salts thereof.
- Glycyrrhetinic acid is a known drug known to have an anti-inflammatory action, an antiallergic action, and the like.
- Glycyrrhizic acid is a known drug known to have an anti-inflammatory action, an antiallergic action, and the like.
- the derivative of glycyrrhetinic acid is not particularly limited as long as it is pharmaceutically acceptable, and specific examples include pyridoxine glycyrrhetinate, stearyl glycyrrhetinate, glyceryl glycyrrhetinate, monoglucuronide glycyrrhetinate and the like. These glycyrrhetinic acid derivatives may be used alone or in combination of two or more.
- the derivative of glycyrrhizic acid is not particularly limited as long as it is pharmaceutically acceptable, and specific examples include methyl glycyrrhizinate and stearyl glycyrrhizinate. These glycyrrhizic acid derivatives may be used alone or in combination of two or more.
- the salt of glycyrrhizic acid, glycyrrhetinic acid and / or a derivative thereof is not particularly limited as long as it is pharmaceutically acceptable. Specific examples include alkali metal salts such as sodium salts and potassium salts; ammonium salts and the like. Can be mentioned. These salts may be used individually by 1 type, and may be used in combination of 2 or more type.
- the emulsified composition of the present invention comprises, as component (A), glycyrrhetic acid, a salt of glycyrrhetic acid, a derivative of glycyrrhetic acid, a salt of a derivative of glycyrrhetinic acid, a glycyrrhizic acid, a salt of glycyrrhizic acid, a derivative of glycyrrhizic acid, and glycyrrhizic acid
- component (A) glycyrrhetic acid, a salt of glycyrrhetic acid, a derivative of glycyrrhetic acid, a salt of a derivative of glycyrrhetinic acid, a glycyrrhizic acid, a salt of glycyrrhizic acid, a derivative of glycyrrhizic acid, and
- glycyrrhetinic acid, glycyrrhizic acid, and salts thereof are preferred; glycyrrhetinic acid and glycyrrhizic acid salts are more preferred; glycyrrhetinic acid and dipotassium glycyrrhizinate are particularly preferred.
- the content of the component (A) is not particularly limited, and may be set as appropriate according to the medicinal effect to be imparted. 01 to 10% by weight, preferably 0.01 to 5% by weight, more preferably 0.05 to 2% by weight.
- Ufenamate is a drug known as a fat-soluble non-steroidal anti-inflammatory drug.
- the content of the component (B) is appropriately set according to the medicinal effect to be exhibited, for example, 1 to 20% by weight, preferably 1 to 6% by weight, more preferably 1 to 5% by weight.
- the ratio of the component (B) to the component (A) is determined according to the contents of the component (A) and the component (B). For example, the total amount of the component (A) is 100.
- the total amount of component (B) per 10 parts by weight is 10 to 200,000 parts by weight, preferably 20 to 60000 parts by weight, more preferably 50 to 10,000 parts by weight.
- the emulsified composition of the present invention contains diphenhydramine and / or a salt thereof.
- the emulsified composition containing the component (A) and the component (B) tends to be destabilized by forming precipitates and precipitates.
- diphenhydramine and / or a salt thereof is added. By containing, it becomes possible to suppress the formation of precipitates and precipitates.
- Diphenhydramine is a known drug known to have an antihistamine action.
- the salt of diphenhydramine is not particularly limited as long as it is pharmaceutically acceptable. Specifically, hydrochloride, citrate, succinate, tartrate, fumarate, maleate, salicylate And acid addition salts such as diphenyl disulfonate, tannate, lauryl sulfate, and sulfate. These salts may be used individually by 1 type, and may be used in combination of 2 or more type.
- the emulsion composition of the present invention may be used by selecting one type from among diphenhydramine and a salt thereof as the component (C), or may be used in combination of two or more types.
- diphenhydramine and diphenhydramine hydrochloride are preferable from the viewpoint of effectively suppressing the formation of precipitates and precipitates.
- the content of the component (C) is not particularly limited.
- the total amount of the component (C) is 0.01 to 5% by weight.
- the content of the component (C) in the emulsion composition of the present invention is preferably 0.1 to 3% by weight, more preferably 0.1%. Up to 2% by weight.
- the ratio of the component (C) to the component (A) is determined according to the contents of the component (A) and the component (C).
- the total amount of the component (A) is 100.
- the total amount of component (C) is 0.1 to 50000 parts by weight per part by weight. From the viewpoint of more effectively suppressing the formation of precipitates and precipitates, the total amount of component (C) is preferably 2 to 30000 parts by weight, more preferably 5 to 5 parts per 100 parts by weight of component (A). 4000 parts by weight can be mentioned.
- the emulsified composition of the present invention may contain a higher alcohol solid at 25 ° C. (hereinafter also referred to as component (D)).
- component (D) By containing a solid higher alcohol at 25 ° C., it is possible to suppress the phase separation of the oil phase and the aqueous phase and to improve the formulation stability.
- the higher alcohol solid at 25 ° C. is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include 12 to 34 carbon atoms.
- Specific examples of the higher alcohol solid at 25 ° C. include lauryl alcohol, mystyryl alcohol, cetanol, stearyl alcohol, cetostearyl alcohol, oleyl alcohol, linoleyl alcohol, behenyl alcohol, arachidyl alcohol, behenyl alcohol, lignoceryl alcohol, ceryl.
- Examples include alcohol, montanyl alcohol, myricyl alcohol, gedyl alcohol and the like. These higher alcohols may be used alone or in combination of two or more.
- a higher alcohol having 16 to 22 carbon atoms preferably lauryl alcohol, myristyl alcohol.
- the content of the component (D) is not particularly limited.
- the total amount of the component (D) is 0.3 to 20% by weight or more.
- the content of the component (D) in the emulsion composition of the present invention is preferably 0.3 to 15% by weight, more preferably 0. 5 to 10% by weight.
- the ratio of the component (D) to the component (A) is determined according to the contents of the component (A) and the component (D).
- the total amount of the component (A) is 100.
- the total amount of component (D) is 3 to 200000 parts by weight per part by weight.
- the total amount of component (D) is preferably 3 to 150,000 parts by weight, more preferably 100 parts by weight of component (A). 25 to 20000 parts by weight may be mentioned.
- the emulsified composition of the present invention may contain polyoxyethylene hydrogenated castor oil (hereinafter sometimes referred to as component (E)). By including polyoxyethylene hydrogenated castor oil, it is possible to further improve the effect of suppressing the formation of precipitates and precipitates.
- the polyoxyethylene hydrogenated castor oil used in the present invention is not particularly limited, and examples thereof include polyoxyethylene (5) hydrogenated castor oil, polyoxyethylene (10) hydrogenated castor oil, and polyoxyethylene (20) hydrogenated castor oil. Oil, polyoxyethylene (30) hydrogenated castor oil, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (50) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (80) hydrogenated castor Oil, polyoxyethylene (100) hydrogenated castor oil, and the like. These polyoxyethylene hydrogenated castor oils may be used individually by 1 type, and may be used in combination of 2 or more type.
- polyoxyethylene (20) hydrogenated castor oil, polyoxyethylene (30) hydrogenated castor oil are preferable.
- the content of the component (E) is not particularly limited.
- the total amount of the component (E) is 0.1 to 10% by weight.
- the content of the component (E) in the emulsion composition of the present invention is preferably 0.1 to 8% by weight, more preferably 0.2%. Up to 5% by weight.
- the ratio of the component (E) to the component (A) is determined depending on the contents of the component (A) and the component (E).
- the total amount of the component (A) is 100.
- the total amount of the component (E) is 1 to 100,000 parts by weight per part by weight. From the viewpoint of more effectively suppressing the formation of precipitates and precipitates, the total amount of component (E) is preferably 2 to 80000 parts by weight, more preferably 10 to 100 parts by weight per 100 parts by weight of component (A). 10,000 parts by weight are mentioned.
- the emulsified composition of the present invention may contain wool wax alcohol (hereinafter sometimes referred to as (F) component).
- wool wax alcohol hereinafter sometimes referred to as (F) component
- component (D) component
- phase separation between the oil phase and the aqueous phase can be more effectively suppressed, and the formulation stability can be dramatically improved.
- Wool wax alcohol is an alcohol component obtained by saponifying and decomposing sheep sebum (wool grease) or lanolin, and is also referred to as lanolin alcohol.
- Wool wax alcohol includes abundant compounds having a steroid skeleton such as cholesterol, lanosterol, dihydrolanosterol, and monohydric or dihydric alcohols having about 14 to 36 carbon atoms (normal alcohol, isoalol, and anteisoalcohol). include.
- the content of the component (F) is not particularly limited.
- the total amount of the component (F) is 0.1 to 20% by weight.
- the content of the component (F) in the emulsion composition of the present invention is preferably 0.1 to 15% by weight, more preferably 0. 3 to 10% by weight.
- the ratio of the component (F) to the component (A) is determined according to the contents of the components (A) and (F).
- the total amount of the component (A) is 100.
- the total amount of component (F) is 1 to 200000 parts by weight per part by weight.
- the total amount of component (F) is preferably 2 to 150,000 parts by weight, more preferably 100 parts by weight of component (A). 15 to 20000 parts by weight may be mentioned.
- the emulsion composition of the present invention may contain a nonpolar oil (hereinafter sometimes referred to as the (G) component) as a component that forms an oil phase.
- a nonpolar oil hereinafter sometimes referred to as the (G) component
- the formation of precipitates and precipitates tends to be noticeable, but in the emulsion composition of the present invention, Even when nonpolar oil is contained, the formation of precipitates and precipitates can be effectively suppressed.
- Nonpolar oil means an oil component having an IOB (inorganic / organic balance) of 0 or more and less than 0.05, and specifically includes hydrocarbon oil extracted from mineral oil.
- hydrocarbon oil is not particularly limited as long as it is pharmaceutically acceptable.
- liquid paraffin liquid normal paraffin, liquid isoparaffin
- ⁇ -olefin oligomer ⁇ -olefin oligomer
- petrolatum ⁇ -olefin oligomer
- microcrystalline wax gelation Examples include hydrocarbons (such as plastibase) and hydrogenated polyisobutene.
- These nonpolar oils may be used alone or in combination of two or more.
- liquid paraffin ⁇ -olefin oligomer, petrolatum, and microcrystalline wax are preferable.
- the content of the component (G) may be appropriately set based on the emulsified form of the emulsion composition, the feeling of use, etc., for example, the total amount of the component (G) is 1 weight. % Or more, preferably 1 to 30% by weight.
- the total amount of the component (G) is 1 weight. % Or more, preferably 1 to 30% by weight.
- the content of the component (G) in the emulsion composition of the present invention is more preferably 5 to 30% by weight, particularly preferably 8 to 30% by weight.
- the emulsified composition of the present invention may contain a polar oil as a component for forming an oil phase.
- the polar oil when the nonpolar oil is contained, the polar oil may not be contained, and the nonpolar oil and the polar oil may be used in combination.
- Polar oil means an oil component having an IOB (inorganic / organic balance) in the range of 0.05 to 1.1.
- the polar oil is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include animal oil, mineral oil, fatty acid alkyl ester, and fatty acid.
- vegetable oils examples include olive oil, wheat germ oil, rice oil, safflower oil, soybean oil, camellia oil, corn oil, rapeseed oil, sesame oil, castor oil, sunflower oil, cottonseed oil, peanut oil, jojoba oil, hydrogenated oil
- These vegetable oils may be used individually by 1 type, and may be used in combination of 2 or more type.
- animal oils include lard, fish oil, beeswax and the like. These animal oils may be used alone or in combination of two or more.
- fatty acid alkyl esters include esters of fatty acids having 4 to 30 carbon atoms and alcohols having 1 to 34 carbon atoms. Specifically, glyceryl triisopalmitate, glyceryl tri-2-ethylhexanoate, glyceryl triisooctanoate, octyldodecyl myristate, diisostearyl malate, neopentyl glycol dioctanoate, dipentaerythritol fatty acid ester, hydroxystearin Cholesteryl adipate, isopropyl adipate, isobutyl adipate, diethyl sebacate, isopropyl sebacate, diisopropyl sebacate, cetyl ethylhexanoate, isopropyl myristate, myristyl myristate, isopropyl palmitate, cetyl palmitate, eth
- fatty acid examples include fatty acids having 4 to 30 carbon atoms, and specific examples include lauric acid, myristic acid, palmitic acid, sebacic acid, oleic acid, linoleic acid, and the like. These fatty acids may be used alone or in combination of two or more.
- fatty acid alkyl esters are preferable.
- polar oils may be used alone or in combination of two or more.
- the polar oil content may be appropriately set in consideration of the emulsified form of the emulsified composition, the feeling of use, etc., for example, 0.5 to 20% by weight, preferably 1 to 20% by weight, more preferably 3 to 15% by weight.
- Emulsion composition of the water present invention contains water as a substrate for forming an aqueous phase.
- the water content may be appropriately set based on the emulsified form of the emulsified composition, the feeling of use, etc., for example, 10 to 90% by weight, preferably 20 to 85% by weight. More preferred is 30 to 85% by weight.
- the emulsion composition of the present invention may contain a surfactant other than the polyoxyethylene hydrogenated castor oil in order to stably form an emulsified state.
- the surfactant (other than polyoxyethylene hydrogenated castor oil) is not particularly limited as long as it is pharmaceutically acceptable.
- Nonionic surfactant (other than polyoxyethylene hydrogenated castor oil), anionic surfactant Any of cationic surfactants and amphoteric surfactants may be used.
- nonionic surfactants other than polyoxyethylene hydrogenated castor oil
- nonionic surfactants include polyoxyethylene (10-50 mol) phytosterol ether, polyoxyethylene (10-50 mol) dihydrocholesterol ether, polyoxyethylene (10-50 mol) 2-octyldodecyl ether, polyoxyethylene (10-50 mol) decyl tetradecyl ether, polyoxyethylene (10-50 mol) oleyl ether, polyoxyethylene (2-50 mol) cetyl ether, Polyoxyethylene (5-50 mol) behenyl ether, polyoxyethylene (5-30 mol) polyoxypropylene (5-30 mol) 2-decyltetradecyl ether, polyoxyethylene (10-50 mol) polyoxypropylene ( 2-30 E) Polyoxyethylene alkyl ethers such as cetyl ether, phosphoric acid / phosphates thereof (such as sodium polyoxyethylene cetyl ether phosphate), polyoxyethylene (20 to 60 mol) sorbitan monoo
- anionic surfactant examples include sodium polyoxyethylene lauryl ether sulfate, sodium lauryl sulfate, sodium myristyl sulfate, sodium N-lauroyl sarcosinate, sodium N-myristol sarcosinate, sodium dodecylbenzene sulfonate, Examples include hydrogenated coconut fatty acid monoglyceride sodium monosulfate, sodium lauryl sulfoacetate, sodium ⁇ -olefin sulfonate, sodium N-palmitoyl glutarate, sodium N-methyl-N-acyl taurate, and the like. These anionic surfactants may be used individually by 1 type, and may be used in combination of 2 or more type.
- cationic surfactant examples include lauryltrimethylammonium chloride, stearyltrimethylammonium chloride, benzethonium chloride, benzalkonium chloride, and stearyldimethylbenzylammonium chloride. These cationic surfactants may be used individually by 1 type, and may be used in combination of 2 or more type.
- amphoteric surfactants include coconut oil fatty acid amidopropyl betaine, lauryl dimethylaminoacetic acid betaine, lauryl dimethylamine oxide, 2-alkyl-N- Examples include carboxymethyl-N-hydroxyethyl imidazolium betaine, N-lauryl diaminoethyl glycine, N-myristyl diaminoethyl glycine, N-alkyl-1-hydroxyethyl imidazoline betaine sodium and the like. These amphoteric surfactants may be used alone or in combination of two or more.
- nonionic surfactants other than polyoxyethylene hydrogenated castor oil are preferable from the viewpoint of stably maintaining the emulsified state.
- surfactants may be used alone or in combination of two or more.
- the content of the surfactant may be appropriately set according to the type of surfactant, the emulsified form, etc. 10% by weight, preferably 1 to 9% by weight, more preferably 2 to 8% by weight.
- the emulsified composition of the present invention may contain a polyhydric alcohol, if necessary, in addition to the above-described components in order to have moisture retention and the like.
- the polyhydric alcohol is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include ethylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol and the like. These polyhydric alcohols may be used individually by 1 type, and may be used in combination of 2 or more type.
- the content of the polyhydric alcohol is not particularly limited.
- it is 0.5 to 30% by weight, preferably 0.5 to 25% by weight, and more preferably 1 to 20% by weight. Can be mentioned.
- the emulsified composition of the present invention may contain a thickener as necessary in order to have a desired viscosity and the like in addition to the components described above.
- the thickener is not particularly limited as long as it is pharmaceutically acceptable.
- xanthan gum, guar gum, locust bean gum, carrageenan dextran, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxyethylcellulose, hydroxypropyl Cellulose, hydroxypropyl methylcellulose, sodium alginate, propylene glycol ester alginate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, carboxyvinyl polymer, alkyl methacrylate copolymer, sodium polyacrylate bentonite, dextrin fatty acid ester, pectin, etc. Can be mentioned.
- xanthan gum and carboxyvinyl polymer are preferable. These thickeners can be used alone or in combination of two or more.
- the content of the thickener may be appropriately set according to the viscosity to be imparted, etc., for example, 0.01 to 5% by weight, preferably 0.1 to 4% by weight. More preferred is 0.1 to 3% by weight.
- the emulsion composition of the present invention may contain other additives usually used for external preparations for skin, etc., if necessary.
- additives include pH adjusters, buffers, solubilizers, chelating agents, preservatives, preservatives, antioxidants, stabilizers, chelating agents, fragrances, and coloring agents.
- the emulsified composition of the present invention may contain a medicinal component other than the components described above, if necessary.
- examples of such drugs include steroid drugs (dexamethasone, dexamethasone hydrochloride, dexamethasone acetate, hydrocortisone hydrochloride, prednisolone valerate, prednisolone acetate, etc.), antihistamines (chlorpheniramine maleate, etc.), local anesthetics (lidocaine, dibucaine, Procaine, tetracaine, bupipacaine, mepipacaine, chloroprocaine, proparacaine, meprilucaine or a salt thereof, alkyl benzoate (for example, ethyl aminobenzoate, diethylaminoethyl parabutylaminobenzoate), orthocaine, oxesazein, oxypolyentoxydecane, Funnel extract, percamin ase
- Antipruritic agents crotamiton, thianthol, etc.
- skin protectants collodion, castor oil, etc.
- blood circulation promoting ingredients nonyl acid vanillylamide, nicotinic acid benzyl ester, capsaicin, capsicum extract, etc.
- vitamins vitamins A, B, C, D, etc.
- mucopolysaccharide sodium chondroitin sulfate, hyaluronic acid, etc.
- the emulsified state of the emulsified composition of the present invention such as emulsified state / form of preparation may be either oil-in-water type or water-in-oil type, preferably oil-in-water type.
- the formulation form of the emulsified composition of the present invention is not particularly limited, and examples thereof include emulsion (emulsion lotion) and cream.
- the emulsified composition of the present invention is suitably used as a skin external preparation applied transdermally.
- Specific examples of the emulsified composition of the present invention include external medicines, cosmetics, skin cleansing agents and the like. Among these preparation forms, an external medicine is preferable.
- the emulsion composition of the present invention can be produced according to a known method for producing an emulsion composition.
- a manufacturing method of the emulsion composition of this invention the method shown below is mentioned, for example.
- (A) component, (B) component, (C) component, nonpolar oil and / or polar oil, and other lipophilic components added as necessary are prepared to prepare an oil phase composition.
- To do. Separately, water and other water-soluble components added as needed are mixed to prepare an aqueous phase composition.
- (E) component and / or surfactant (other than (E) component) are included, these are added to either or both of the oil phase composition and the aqueous phase composition.
- the obtained oil phase composition and aqueous phase composition are mixed and emulsified by an emulsification technique such as a homogenizer to produce the emulsified composition of the present invention.
- the present invention further relates to an emulsion comprising (A) at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, and (B) ufenamate.
- a method for suppressing the formation of precipitates and precipitates comprising: (A) at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof; and (B) Provided is a method for suppressing the formation of precipitates and precipitates, which comprises blending (C) diphenhydramine and / or a salt thereof together with ufenamate.
- the present invention further includes (A) glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof selected from the group consisting of a precipitate and a precipitate, and a method for suppressing phase separation between an oil phase and an aqueous phase.
- the emulsion composition containing 1 type and (B) Ufenamate is a method for suppressing the formation of precipitates and precipitates, and the phase separation of the oil phase and the aqueous phase, comprising (A) glycyrrhetinic acid, glycyrrhizic acid, (C) diphenhydramine and / or a salt thereof, and (D) a higher alcohol that is solid at 25 ° C., together with at least one selected from the group consisting of derivatives, and salts thereof, and (B) ufenamate.
- the present invention provides a method for suppressing the formation of precipitates and precipitates, and the phase separation of an oil phase and an aqueous phase.
- Test Example A creamy oil-in-water emulsion composition having the composition shown in Table 1 was produced and evaluated for the degree of precipitation, the degree of precipitation, and the degree of phase separation.
- the production method and test method of the creamy oil-in-water emulsion composition are as follows.
- phase separation between the oil phase and the aqueous phase could be suppressed (Examples 7 to 14).
- the emulsion composition containing wool wax alcohol in addition to these components the effect of suppressing the phase separation between the oil phase and the aqueous phase was further improved (Examples 12 and 13).
- Formulation Example An oil-in-water emulsion composition having the composition shown in Table 2 was prepared. Each of these preparations is an emulsified composition in which the formation of precipitates and precipitates is suppressed as in the case of the test example.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
本発明は、グリチルレチン酸、グリチルリチン酸、それらの誘導体、及び/又はそれらの塩と、ウフェナマートとを含み、析出物や沈殿の生成が抑制されている乳化組成物に関する。 The present invention relates to an emulsified composition containing glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and / or salts thereof, and ufenamate, and suppressing the formation of precipitates and precipitates.
非ステロイド性抗炎症剤は、ステロイド性抗炎症剤で見られるような重篤な副作用の懸念が殆どなく、使用量や使用期間等の制約も少ないため、発疹、発赤、乾燥性皮膚炎、アトピー性皮膚炎等の炎症性皮膚疾患の緩和を目的とした外用剤でも汎用されている。 Non-steroidal anti-inflammatory drugs have almost no serious side effects as seen with steroidal anti-inflammatory drugs, and there are few restrictions on the amount and period of use, so rash, redness, dry dermatitis, atopy It is also widely used in external preparations for the purpose of alleviating inflammatory skin diseases such as atopic dermatitis.
非ステロイド性抗炎症剤の内、グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩(以下、「グリチルレチン酸類」と表記することもある)には、抗炎症作用に加えて、組織修復作用に優れており、外用剤に広く使用されている。また、非ステロイド性抗炎症剤の内、ウフェナマートは、フルフェナム酸と同等の抗炎症作用を有し、局所刺激作用がフルフェナム酸よりも低いため、デリケートな肌への適用や長期間の使用に適しており、外用剤に広く使用されている。 Among non-steroidal anti-inflammatory agents, glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof (hereinafter sometimes referred to as “glycyrrhetinic acids”) have a tissue repair action in addition to an anti-inflammatory action. And is widely used in external preparations. Of the non-steroidal anti-inflammatory agents, ufenamate has the same anti-inflammatory effect as flufenamic acid and has lower local irritation than flufenamic acid, making it suitable for delicate skin applications and long-term use. It is widely used for external preparations.
一方、非ステロイド性抗炎症剤は、ステロイド性抗炎症剤に比べて抗炎症作用が緩慢であるという欠点がある。そこで、近年、抗炎症作用を効果的に発揮さるために、作用機序が異なる2種以上の非ステロイド性抗炎症剤を組み合わせることが試みられており、グリチルレチン酸類とウフェナマートとを併用した外用剤が開発されている。 On the other hand, non-steroidal anti-inflammatory agents have a drawback that their anti-inflammatory action is slower than steroidal anti-inflammatory agents. Therefore, in recent years, in order to effectively exert an anti-inflammatory effect, an attempt has been made to combine two or more types of non-steroidal anti-inflammatory agents having different action mechanisms, and an external preparation using a combination of glycyrrhetinic acids and ufenamate. Has been developed.
また、グリチルレチン酸類やウフェナマートは、製剤中で不安定化され易く、析出物や沈殿を生じることがあるため、これらを含む外用剤では、製剤安定性を高めた処方設計が必要とされている。そこで、従来、グリチルレチン酸類やウフェナマートを含む外用剤において、製剤安定性を高める製剤技術が検討されている。例えば、特許文献1には、ウフェナマート等の水難溶性有効成分と、非イオン性界面活性剤と、グリチルレチン酸類等の助剤と、水とを含むゲル軟膏は、水難溶性有効成分を安定に保持できることが報告されている。しかしながら、特許文献1に開示されている製剤技術では、ゲル軟膏にしか適用できないため汎用性に欠けており、更にその製剤安定性の点でも必ずしも満足できるとはいえないのが現状である。 In addition, glycyrrhetinic acids and ufenamate are easily destabilized in the preparation and may cause precipitates and precipitates. Therefore, for external preparations containing these, a formulation design with improved preparation stability is required. Therefore, conventionally, preparation techniques for improving the preparation stability have been studied for external preparations containing glycyrrhetinic acids and ufenamate. For example, Patent Document 1 discloses that a gel ointment containing a poorly water-soluble active ingredient such as ufenamate, a nonionic surfactant, an auxiliary agent such as glycyrrhetinic acid, and water can stably hold the poorly water-soluble active ingredient. Has been reported. However, since the formulation technique disclosed in Patent Document 1 can be applied only to gel ointment, it lacks versatility, and it is not always satisfactory in terms of formulation stability.
本発明の目的は、グリチルレチン酸、グリチルリチン酸、それらの誘導体、及び/又はこれらの塩と、ウフェナマートとを含み、析出物や沈殿の生成が抑制されている乳化組成物を提供することである。 An object of the present invention is to provide an emulsified composition containing glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and / or their salts, and ufenamate, and suppressing the formation of precipitates and precipitates.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、グリチルレチン酸、グリチルリチン酸、これらの誘導体、及び/又はそれらの塩と、ウフェナマートとを含む乳化組成物において、ジフェンヒドラミン及び/又はその塩を配合することによって、析出物や沈殿の生成を抑制できることを見出した。更に、本発明者は、前記乳化組成物に、ジフェンヒドラミン及び/又はその塩と共にポリオキシエチレン硬化ヒマシ油を配合することによって、析出物や沈殿の生成を抑制すると共に、油相と水相の分離を抑制でき、乳化状態を安定に維持する効果が向上することをも見出した。本発明は、これらの知見に基づいて更に検討を重ねることにより完成したものである。 The present inventor conducted intensive studies to solve the above-mentioned problems. As a result, in an emulsion composition containing glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and / or salts thereof, and ufenamate, diphenhydramine and / or its It discovered that the production | generation of a precipitate and precipitation can be suppressed by mix | blending salt. Furthermore, the present inventor suppresses the formation of precipitates and precipitates by mixing polyoxyethylene hydrogenated castor oil together with diphenhydramine and / or a salt thereof into the emulsified composition, and separates the oil phase from the water phase. It has also been found that the effect of stably maintaining the emulsified state can be improved. The present invention has been completed by further studies based on these findings.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項1. (A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種と、(B)ウフェナマートと、(C)ジフェンヒドラミン及び/又はその塩を含有する、乳化組成物。
項2. (D)25℃で固体の高級アルコールを含有する、項1に記載の乳化組成物。
項3. (E)ポリオキシエチレン硬化ヒマシ油を含有する、項2に記載の乳化組成物。
項4. (F)ウールワックスアルコールを含有する、項2又は3に記載の乳化組成物。
項5. (G)無極性油を含有する、項1~4のいずれかに記載の乳化組成物。
項6. 水中油型乳化組成物である、項1~5のいずれかに記載の乳化組成物。
項7. 皮膚外用剤である、項1~6のいずれかに記載の乳化組成物。
項8. (A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(B)ウフェナマートを含む乳化組成物において、析出物及び沈殿の生成を抑制する方法であって、 (A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(A)ウフェナマートと共に、(C)ジフェンヒドラミン及び/又はその塩を配合する、方法。
項9. (A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(B)ウフェナマートを含む乳化組成物において、析出物及び沈殿の生成、並びに油相と水相の相分離を抑制する方法であって、
(A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(B)ウフェナマートと共に、(C)ジフェンヒドラミン及び/又はその塩、並びに(D)25℃で固体の高級アルコールを配合する、方法。
That is, this invention provides the invention of the aspect hung up below.
Item 1. (A) Emulsifying composition containing at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, (B) ufenamate, and (C) diphenhydramine and / or a salt thereof. object.
Item 2. Item (D) The emulsified composition according to Item 1, containing a higher alcohol that is solid at 25 ° C.
Item 3. Item (E) The emulsified composition according to Item 2, comprising polyoxyethylene hydrogenated castor oil.
Item 4. (F) The emulsion composition of claim | item 2 or 3 containing wool wax alcohol.
Item 5. Item 5. The emulsified composition according to any one of Items 1 to 4, comprising a nonpolar oil.
Item 6. Item 6. The emulsion composition according to any one of Items 1 to 5, which is an oil-in-water emulsion composition.
Item 7. Item 7. The emulsified composition according to any one of Items 1 to 6, which is an external preparation for skin.
Item 8. (A) At least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, and (B) a method for suppressing the formation of precipitates and precipitates in an emulsified composition containing ufenamate And (A) glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and at least one selected from the group consisting of these salts, and (A) Ufenamate and (C) diphenhydramine and / or a salt thereof. how to.
Item 9. (A) At least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, and (B) formation of precipitates and precipitates, and an oil phase in an emulsion composition containing ufenamate A method of suppressing phase separation between the water phase and the water phase,
(A) glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and at least one selected from the group consisting of these salts, and (B) ufenamate, (C) diphenhydramine and / or a salt thereof, and (D) 25 A method of blending a higher alcohol that is solid at ℃.
本発明の乳化組成物は、グリチルレチン酸類とウフェナマートとを含んでいながらも、ジフェンヒドラミン及び/又はその塩を含むことによって、析出物や沈殿の生成を抑制することができる。また、本発明の乳化組成物は、更に25℃で固体の高級アルコールを含むことによって、油相と水相の分離も抑制でき、優れた製剤安定性を備えることができる。 The emulsified composition of the present invention can suppress the formation of precipitates and precipitates by containing diphenhydramine and / or a salt thereof while containing glycyrrhetinic acids and ufenamate. Moreover, the emulsion composition of this invention can also suppress isolation | separation of an oil phase and an aqueous phase by containing a solid higher alcohol at 25 degreeC, and can be equipped with the outstanding formulation stability.
1.乳化組成物
本発明の乳化組成物は、グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種(以下、(A)成分と表記することがある)と、ウフェナマート(以下、(B)成分と表記することがある)と、ジフェンヒドラミン及び/又はその塩(以下、(C)成分と表記することがある)を含有することを特徴とする。以下、本発明の乳化組成物について詳述する。
1. Emulsified composition The emulsified composition of the present invention comprises at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof (hereinafter sometimes referred to as component (A)). And Ufenamate (hereinafter sometimes referred to as the component (B)) and diphenhydramine and / or a salt thereof (hereinafter sometimes referred to as the component (C)). Hereinafter, the emulsified composition of the present invention will be described in detail.
(A)グリチルリチン酸類
本発明の乳化組成物は、グリチルレチン酸、グリチルリチン酸、それらの誘導体、及び/又はそれらの塩を含有する。
(A) Glycyrrhizic acids The emulsified composition of the present invention contains glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and / or salts thereof.
グリチルレチン酸は、抗炎症作用や抗アレルギー作用等を有することが知られている公知の薬剤である。 Glycyrrhetinic acid is a known drug known to have an anti-inflammatory action, an antiallergic action, and the like.
グリチルリチン酸は、抗炎症作用や抗アレルギー作用等を有することが知られている公知の薬剤である。 Glycyrrhizic acid is a known drug known to have an anti-inflammatory action, an antiallergic action, and the like.
グリチルレチン酸の誘導体としては、薬学的に許容されることを限度として特に制限されないが、具体的には、グリチルレチン酸ピリドキシン、グリチルレチン酸ステアリル、グリチルレチン酸グリセリル、グリチルレチン酸モノグルクロニド等が挙げられる。これらのグリチルレチン酸の誘導体は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The derivative of glycyrrhetinic acid is not particularly limited as long as it is pharmaceutically acceptable, and specific examples include pyridoxine glycyrrhetinate, stearyl glycyrrhetinate, glyceryl glycyrrhetinate, monoglucuronide glycyrrhetinate and the like. These glycyrrhetinic acid derivatives may be used alone or in combination of two or more.
グリチルリチン酸の誘導体としては、薬学的に許容されることを限度として特に制限されないが、具体的には、グリチルリチン酸メチル、グリチルリチン酸ステアリル等が挙げられる。これらのグリチルリチン酸の誘導体は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The derivative of glycyrrhizic acid is not particularly limited as long as it is pharmaceutically acceptable, and specific examples include methyl glycyrrhizinate and stearyl glycyrrhizinate. These glycyrrhizic acid derivatives may be used alone or in combination of two or more.
グリチルリチン酸、グリチルレチン酸及び/又はその誘導体の塩としては、薬学的に許容されるものである限り特に制限されないが、具体的には、ナトリウム塩、カリウム塩等のアルカリ金属塩;アンモニウム塩等が挙げられる。これらの塩は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The salt of glycyrrhizic acid, glycyrrhetinic acid and / or a derivative thereof is not particularly limited as long as it is pharmaceutically acceptable. Specific examples include alkali metal salts such as sodium salts and potassium salts; ammonium salts and the like. Can be mentioned. These salts may be used individually by 1 type, and may be used in combination of 2 or more type.
本発明の乳化組成物は、(A)成分として、グリチルレチン酸、グリチルレチン酸の塩、グリチルレチン酸の誘導体、グリチルレチン酸の誘導体の塩、グリチルリチン酸、グリチルリチン酸の塩、グリチルリチン酸の誘導体、及びグリチルリチン酸の誘導体の塩の中から、1種を選択して使用してもよく、2種以上を組み合わせて使用してもよい。 The emulsified composition of the present invention comprises, as component (A), glycyrrhetic acid, a salt of glycyrrhetic acid, a derivative of glycyrrhetic acid, a salt of a derivative of glycyrrhetinic acid, a glycyrrhizic acid, a salt of glycyrrhizic acid, a derivative of glycyrrhizic acid, and glycyrrhizic acid Of these derivative salts, one may be selected and used, or two or more may be used in combination.
これらの(A)成分の中でも、好ましくは、グリチルレチン酸、グリチルリチン酸、及びこれらの塩;更に好ましくは、グリチルレチン酸、グリチルリチン酸の塩;特に好ましくは、グリチルレチン酸、グリチルリチン酸ジカリウムが挙げられる。 Among these components (A), glycyrrhetinic acid, glycyrrhizic acid, and salts thereof are preferred; glycyrrhetinic acid and glycyrrhizic acid salts are more preferred; glycyrrhetinic acid and dipotassium glycyrrhizinate are particularly preferred.
本発明の乳化組成物において、(A)成分の含有量については、特に制限されず、付与すべき薬効等に応じて適宜設定すればよいが、例えば、(B)成分の総量で、0.01~10重量%、好ましくは0.01~5重量%、更に好ましくは0.05~2重量%が挙げられる。 In the emulsified composition of the present invention, the content of the component (A) is not particularly limited, and may be set as appropriate according to the medicinal effect to be imparted. 01 to 10% by weight, preferably 0.01 to 5% by weight, more preferably 0.05 to 2% by weight.
(B)ウフェナマート
本発明の乳化組成物は、ウフェナマートを含有する。ウフェナマートは、脂溶性の非ステロイド性抗炎症薬として公知の薬剤である。
(B) Ufenamate The emulsified composition of the present invention contains ufenamate. Ufenamate is a drug known as a fat-soluble non-steroidal anti-inflammatory drug.
本発明の乳化組成物において、(B)成分の含有量については、発揮させるべき薬効等に応じて適宜設定されるが、例えば1~20重量%、好ましくは1~6重量%、更に好ましくは1~5重量%が挙げられる。 In the emulsified composition of the present invention, the content of the component (B) is appropriately set according to the medicinal effect to be exhibited, for example, 1 to 20% by weight, preferably 1 to 6% by weight, more preferably 1 to 5% by weight.
本発明の乳化組成物において、(A)成分に対する(B)成分の比率については、(A)成分及び(B)成分の各含有量に応じて定まるが、例えば、(A)成分の総量100重量部当たり、(B)成分の総量が10~200000重量部、好ましくは20~60000重量部、更に好ましくは50~10000重量部が挙げられる。 In the emulsion composition of the present invention, the ratio of the component (B) to the component (A) is determined according to the contents of the component (A) and the component (B). For example, the total amount of the component (A) is 100. The total amount of component (B) per 10 parts by weight is 10 to 200,000 parts by weight, preferably 20 to 60000 parts by weight, more preferably 50 to 10,000 parts by weight.
(C)ジフェンヒドラミン及び/又はその塩
本発明の乳化組成物は、ジフェンヒドラミン及び/又はその塩を含有する。前記(A)成分及び(B)成分を含有する乳化組成物は、析出物や沈殿を生成して不安定化する傾向があるが、本発明の乳化組成物では、ジフェンヒドラミン及び/又はその塩を含有することによって、析出物や沈殿の生成を抑制することが可能になっている。
(C) Diphenhydramine and / or salt thereof The emulsified composition of the present invention contains diphenhydramine and / or a salt thereof. The emulsified composition containing the component (A) and the component (B) tends to be destabilized by forming precipitates and precipitates. However, in the emulsified composition of the present invention, diphenhydramine and / or a salt thereof is added. By containing, it becomes possible to suppress the formation of precipitates and precipitates.
ジフェンヒドラミンは、抗ヒスタミン作用があることが知られている公知の薬剤である。 Diphenhydramine is a known drug known to have an antihistamine action.
ジフェンヒドラミンの塩としては、薬学的に許容されるものである限り特に制限されないが、具体的には、塩酸塩、クエン酸塩、コハク酸塩、酒石酸塩、フマル酸塩、マレイン酸塩、サリチル酸塩、ジフェニルジスルホン酸塩、タンニン酸塩、ラウリル硫酸塩、硫酸塩等の酸付加塩が挙げられる。これらの塩は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The salt of diphenhydramine is not particularly limited as long as it is pharmaceutically acceptable. Specifically, hydrochloride, citrate, succinate, tartrate, fumarate, maleate, salicylate And acid addition salts such as diphenyl disulfonate, tannate, lauryl sulfate, and sulfate. These salts may be used individually by 1 type, and may be used in combination of 2 or more type.
本発明の乳化組成物は、(C)成分として、ジフェンヒドラミン及びその塩の中から、1種を選択して使用してもよく、2種以上を組み合わせて使用してもよい。 The emulsion composition of the present invention may be used by selecting one type from among diphenhydramine and a salt thereof as the component (C), or may be used in combination of two or more types.
これらの(C)成分の中でも、析出物や沈殿の生成を効果的に抑制させるという観点から、好ましくはジフェンヒドラミン、塩酸ジフェンヒドラミンが挙げられる。 Among these components (C), diphenhydramine and diphenhydramine hydrochloride are preferable from the viewpoint of effectively suppressing the formation of precipitates and precipitates.
本発明の乳化組成物において、(C)成分の含有量については、特に制限されないが、例えば、(C)成分の総量で、0.01~5重量%が挙げられる。析出物や沈殿の生成をより一層効果的に抑制させるという観点から、本発明の乳化組成物における(C)成分の含有量として、好ましくは0.1~3重量%、更に好ましくは0.1~2重量%が挙げられる。 In the emulsified composition of the present invention, the content of the component (C) is not particularly limited. For example, the total amount of the component (C) is 0.01 to 5% by weight. From the viewpoint of more effectively suppressing the formation of precipitates and precipitates, the content of the component (C) in the emulsion composition of the present invention is preferably 0.1 to 3% by weight, more preferably 0.1%. Up to 2% by weight.
本発明の乳化組成物において、(A)成分に対する(C)成分の比率については、(A)成分及び(C)成分の各含有量に応じて定まるが、例えば、(A)成分の総量100重量部当たり、(C)成分の総量が0.1~50000重量部が挙げられる。析出物や沈殿の生成をより一層効果的に抑制させるという観点から、(A)成分の総量100重量部当たり、(C)成分の総量が、好ましくは2~30000重量部、更に好ましくは5~4000重量部が挙げられる。 In the emulsion composition of the present invention, the ratio of the component (C) to the component (A) is determined according to the contents of the component (A) and the component (C). For example, the total amount of the component (A) is 100. The total amount of component (C) is 0.1 to 50000 parts by weight per part by weight. From the viewpoint of more effectively suppressing the formation of precipitates and precipitates, the total amount of component (C) is preferably 2 to 30000 parts by weight, more preferably 5 to 5 parts per 100 parts by weight of component (A). 4000 parts by weight can be mentioned.
(D)25℃で固体の高級アルコール
本発明の乳化組成物は、25℃で固体の高級アルコール(以下、(D)成分と表記することもある)を含有してもよい。25℃で固体の高級アルコールを含有させることによって、油相と水相の相分離を抑制して、製剤安定性を向上させることが可能になる。
(D) Higher alcohol solid at 25 ° C. The emulsified composition of the present invention may contain a higher alcohol solid at 25 ° C. (hereinafter also referred to as component (D)). By containing a solid higher alcohol at 25 ° C., it is possible to suppress the phase separation of the oil phase and the aqueous phase and to improve the formulation stability.
25℃で固体の高級アルコールとしては、薬学的に許容されるものである限り特に制限されないが、例えば、炭素数12~34が挙げられる。25℃で固体の高級アルコールとして、具体的には、ラウリルアルコール、ミスチリルアルコール、セタノール、ステアリルアルコール、セトステアリルアルコール、オレイルアルコール、リノリルアルコール、ベヘニルアルコール、アラキジルアルコール、ベヘニルアルコール、リグノセリルアルコール、セリルアルコール、モンタニルアルコール、ミリシルアルコール、ゲジルアルコール等が挙げられる。これらの高級アルコールは、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The higher alcohol solid at 25 ° C. is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include 12 to 34 carbon atoms. Specific examples of the higher alcohol solid at 25 ° C. include lauryl alcohol, mystyryl alcohol, cetanol, stearyl alcohol, cetostearyl alcohol, oleyl alcohol, linoleyl alcohol, behenyl alcohol, arachidyl alcohol, behenyl alcohol, lignoceryl alcohol, ceryl. Examples include alcohol, montanyl alcohol, myricyl alcohol, gedyl alcohol and the like. These higher alcohols may be used alone or in combination of two or more.
これらの高級アルコールの中でも、油相と水相の相分離を抑制する効果をより一層向上させるという観点から、好ましくは、炭素数16~22の高級アルコール、更に好ましくは、ラウリルアルコール、ミスチリルアルコール、セタノール、ステアリルアルコール、セトステアリルアルコール、ベヘニルアルコール;更に好ましくは、セタノール、ステアリルアルコール、ステアリルアルコール、ベヘニルアルコールが挙げられる。 Among these higher alcohols, from the viewpoint of further improving the effect of suppressing the phase separation between the oil phase and the aqueous phase, preferably a higher alcohol having 16 to 22 carbon atoms, more preferably lauryl alcohol, myristyl alcohol. , Cetanol, stearyl alcohol, cetostearyl alcohol, behenyl alcohol; more preferably cetanol, stearyl alcohol, stearyl alcohol, behenyl alcohol.
本発明の乳化組成物において、(D)成分の含有量については、特に制限されないが、例えば、(D)成分の総量で、0.3~20重量%以上が挙げられる。油相と水相の相分離をより一層効果的に抑制させるという観点から、本発明の乳化組成物における(D)成分の含有量として、好ましくは0.3~15重量%、更に好ましくは0.5~10重量%が挙げられる。 In the emulsified composition of the present invention, the content of the component (D) is not particularly limited. For example, the total amount of the component (D) is 0.3 to 20% by weight or more. From the viewpoint of more effectively suppressing the phase separation of the oil phase and the aqueous phase, the content of the component (D) in the emulsion composition of the present invention is preferably 0.3 to 15% by weight, more preferably 0. 5 to 10% by weight.
本発明の乳化組成物において、(A)成分に対する(D)成分の比率については、(A)成分及び(D)成分の各含有量に応じて定まるが、例えば、(A)成分の総量100重量部当たり、(D)成分の総量が3~200000重量部が挙げられる。油相と水相の相分離をより一層効果的に抑制させるという観点から、(A)成分の総量100重量部当たり、(D)成分の総量が、好ましくは3~150000重量部、更に好ましくは25~20000重量部が挙げられる。 In the emulsion composition of the present invention, the ratio of the component (D) to the component (A) is determined according to the contents of the component (A) and the component (D). For example, the total amount of the component (A) is 100. The total amount of component (D) is 3 to 200000 parts by weight per part by weight. From the viewpoint of more effectively suppressing the phase separation between the oil phase and the aqueous phase, the total amount of component (D) is preferably 3 to 150,000 parts by weight, more preferably 100 parts by weight of component (A). 25 to 20000 parts by weight may be mentioned.
(E)ポリオキシエチレン硬化ヒマシ油
本発明の乳化組成物は、ポリオキシエチレン硬化ヒマシ油(以下、(E)成分と表記することもある)を含有してもよい。ポリオキシエチレン硬化ヒマシ油を含有させることによって、析出物や沈殿の生成を抑制する効果を更に向上させることが可能になる。
(E) Polyoxyethylene hydrogenated castor oil The emulsified composition of the present invention may contain polyoxyethylene hydrogenated castor oil (hereinafter sometimes referred to as component (E)). By including polyoxyethylene hydrogenated castor oil, it is possible to further improve the effect of suppressing the formation of precipitates and precipitates.
本発明で使用されるポリオキシエチレン硬化ヒマシ油としては、特に制限されないが、例えば、ポリオキシエチレン(5)硬化ヒマシ油、ポリオキシエチレン(10)硬化ヒマシ油、ポリオキシエチレン(20)硬化ヒマシ油、ポリオキシエチレン(30)硬化ヒマシ油、ポリオキシエチレン(40)硬化ヒマシ油、ポリオキシエチレン(50)硬化ヒマシ油、ポリオキシエチレン(60)硬化ヒマシ油、ポリオキシエチレン(80)硬化ヒマシ油、ポリオキシエチレン(100)硬化ヒマシ油等が挙げられる。これらのポリオキシエチレン硬化ヒマシ油は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The polyoxyethylene hydrogenated castor oil used in the present invention is not particularly limited, and examples thereof include polyoxyethylene (5) hydrogenated castor oil, polyoxyethylene (10) hydrogenated castor oil, and polyoxyethylene (20) hydrogenated castor oil. Oil, polyoxyethylene (30) hydrogenated castor oil, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (50) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (80) hydrogenated castor Oil, polyoxyethylene (100) hydrogenated castor oil, and the like. These polyoxyethylene hydrogenated castor oils may be used individually by 1 type, and may be used in combination of 2 or more type.
これらのポリオキシエチレン硬化ヒマシ油の中でも、析出物や沈殿の生成をより一層効果的に抑制させるという観点から、好ましくは、ポリオキシエチレン(20)硬化ヒマシ油、ポリオキシエチレン(30)硬化ヒマシ油、ポリオキシエチレン(40)硬化ヒマシ油、ポリオキシエチレン(50)硬化ヒマシ油、ポリオキシエチレン(60)硬化ヒマシ油、ポリオキシエチレン(80)硬化ヒマシ油、ポリオキシエチレン(100)硬化ヒマシ油;更に好ましくは、ポリオキシエチレン(50)硬化ヒマシ油が挙げられる。 Among these polyoxyethylene hydrogenated castor oils, from the viewpoint of more effectively suppressing the formation of precipitates and precipitates, polyoxyethylene (20) hydrogenated castor oil, polyoxyethylene (30) hydrogenated castor oil are preferable. Oil, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (50) hydrogenated castor oil, polyoxyethylene (60) hydrogenated castor oil, polyoxyethylene (80) hydrogenated castor oil, polyoxyethylene (100) hydrogenated castor oil More preferably, polyoxyethylene (50) hydrogenated castor oil is used.
本発明の乳化組成物において、(E)成分の含有量については、特に制限されないが、例えば、(E)成分の総量で、0.1~10重量%が挙げられる。析出物や沈殿の生成をより一層効果的に抑制させるという観点から、本発明の乳化組成物における(E)成分の含有量として、好ましくは0.1~8重量%、更に好ましくは0.2~5重量%が挙げられる。 In the emulsified composition of the present invention, the content of the component (E) is not particularly limited. For example, the total amount of the component (E) is 0.1 to 10% by weight. From the viewpoint of more effectively suppressing the formation of precipitates and precipitates, the content of the component (E) in the emulsion composition of the present invention is preferably 0.1 to 8% by weight, more preferably 0.2%. Up to 5% by weight.
本発明の乳化組成物において、(A)成分に対する(E)成分の比率については、(A)成分及び(E)成分の各含有量に応じて定まるが、例えば、(A)成分の総量100重量部当たり、(E)成分の総量が1~100000重量部が挙げられる。析出物や沈殿の生成をより一層効果的に抑制させるという観点から、(A)成分の総量100重量部当たり、(E)成分の総量が、好ましくは2~80000重量部、更に好ましくは10~10000重量部が挙げられる。 In the emulsion composition of the present invention, the ratio of the component (E) to the component (A) is determined depending on the contents of the component (A) and the component (E). For example, the total amount of the component (A) is 100. The total amount of the component (E) is 1 to 100,000 parts by weight per part by weight. From the viewpoint of more effectively suppressing the formation of precipitates and precipitates, the total amount of component (E) is preferably 2 to 80000 parts by weight, more preferably 10 to 100 parts by weight per 100 parts by weight of component (A). 10,000 parts by weight are mentioned.
(F)ウールワックスアルコール
本発明の乳化組成物は、ウールワックスアルコール(以下、(F)成分と表記することもある)を含有してもよい。特に、前述する(D)成分と共に、ウールワックスアルコールを含有させることによって、油相と水相の相分離をより一層効果的に抑制でき、製剤安定性を飛躍的に向上させることが可能になる。
(F) Wool Wax Alcohol The emulsified composition of the present invention may contain wool wax alcohol (hereinafter sometimes referred to as (F) component). In particular, by including wool wax alcohol together with the component (D) described above, phase separation between the oil phase and the aqueous phase can be more effectively suppressed, and the formulation stability can be dramatically improved. .
ウールワックスアルコールは、羊の皮脂(ウールグリース)又はラノリンをけん化分解して得られるアルコール成分であり、ラノリンアルコールとも称されている成分である。 Wool wax alcohol is an alcohol component obtained by saponifying and decomposing sheep sebum (wool grease) or lanolin, and is also referred to as lanolin alcohol.
ウールワックスアルコールには、コレステロール、ラノステロール、ジヒドロラノステロール等のステロイド骨格を有する化合物を豊富に含み、炭素数14~36程度の1価又は2価のアルコール(ノルマルアルコール、イソアルオール、及びアンテイソアルコール)が含まれている。 Wool wax alcohol includes abundant compounds having a steroid skeleton such as cholesterol, lanosterol, dihydrolanosterol, and monohydric or dihydric alcohols having about 14 to 36 carbon atoms (normal alcohol, isoalol, and anteisoalcohol). include.
本発明の乳化組成物において、(F)成分の含有量については、特に制限されないが、例えば、(F)成分の総量で、0.1~20重量%が挙げられる。油相と水相の相分離をより一層効果的に抑制させるという観点から、本発明の乳化組成物における(F)成分の含有量として、好ましくは0.1~15重量%、更に好ましくは0.3~10重量%が挙げられる。 In the emulsified composition of the present invention, the content of the component (F) is not particularly limited. For example, the total amount of the component (F) is 0.1 to 20% by weight. From the viewpoint of more effectively suppressing the phase separation of the oil phase and the aqueous phase, the content of the component (F) in the emulsion composition of the present invention is preferably 0.1 to 15% by weight, more preferably 0. 3 to 10% by weight.
本発明の乳化組成物において、(A)成分に対する(F)成分の比率については、(A)成分及び(F)成分の各含有量に応じて定まるが、例えば、(A)成分の総量100重量部当たり、(F)成分の総量が1~200000重量部が挙げられる。油相と水相の相分離をより一層効果的に抑制させるという観点から、(A)成分の総量100重量部当たり、(F)成分の総量が、好ましくは2~150000重量部、更に好ましくは15~20000重量部が挙げられる。 In the emulsion composition of the present invention, the ratio of the component (F) to the component (A) is determined according to the contents of the components (A) and (F). For example, the total amount of the component (A) is 100. The total amount of component (F) is 1 to 200000 parts by weight per part by weight. From the viewpoint of more effectively suppressing phase separation between the oil phase and the aqueous phase, the total amount of component (F) is preferably 2 to 150,000 parts by weight, more preferably 100 parts by weight of component (A). 15 to 20000 parts by weight may be mentioned.
(G)無極性油
本発明の乳化組成物は、油相を形成する成分として、無極性油(以下、(G)成分と表記することもある)が含まれていてもよい。従来技術では、(A)成分及び(B)成分を含む乳化組成物において無極性油を含有させると、析出物や沈殿の生成が顕著になる傾向が現れるが、本発明の乳化組成物では、無極性油を含んでいても、析出物や沈殿の生成を効果的に抑制することができる。
(G) Nonpolar Oil The emulsion composition of the present invention may contain a nonpolar oil (hereinafter sometimes referred to as the (G) component) as a component that forms an oil phase. In the prior art, when a nonpolar oil is included in the emulsion composition containing the component (A) and the component (B), the formation of precipitates and precipitates tends to be noticeable, but in the emulsion composition of the present invention, Even when nonpolar oil is contained, the formation of precipitates and precipitates can be effectively suppressed.
無極性油とは、IOB(無機性/有機性のバランス)が0以上0.05未満である油分を意味し、具体的には、鉱物油から抽出された炭化水素油が挙げられる。このような炭化水素油としては、薬学的に許容されることを限度として特に制限されないが、例えば、流動パラフィン(流動ノルマルパラフィン、流動イソパラフィン)、α-オレフィンオリゴマー、ワセリン、マイクロクリスタリンワックス、ゲル化炭化水素(プラスチベース等)、水添ポリイソブテン等が挙げられる。これらの無極性油は、1腫単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Nonpolar oil means an oil component having an IOB (inorganic / organic balance) of 0 or more and less than 0.05, and specifically includes hydrocarbon oil extracted from mineral oil. Such hydrocarbon oil is not particularly limited as long as it is pharmaceutically acceptable. For example, liquid paraffin (liquid normal paraffin, liquid isoparaffin), α-olefin oligomer, petrolatum, microcrystalline wax, gelation Examples include hydrocarbons (such as plastibase) and hydrogenated polyisobutene. These nonpolar oils may be used alone or in combination of two or more.
これら無極性油の中でも、好ましくは、流動パラフィン、α-オレフィンオリゴマー、ワセリン、マイクロクリスタリンワックスが挙げられる。 Among these nonpolar oils, liquid paraffin, α-olefin oligomer, petrolatum, and microcrystalline wax are preferable.
本発明の乳化組成物において、(G)成分の含有量については、乳化組成物の乳化形態、使用感等を踏まえて適宜設定すればよいが、例えば、(G)成分の総量で、1重量%以上、好ましくは1~30重量%が挙げられる。また、従来技術では、(A)成分及び(B)成分を含む乳化組成物において(G)成分が5重量%以上、特に8重量%以上含まれている場合には、析出物や沈殿の生成が格段に促進される傾向があるが、本発明の乳化組成物では、このように(G)成分が高含有量で含まれていても、析出物や沈殿の生成を抑制可能になっている。このような本発明の効果を鑑みれば、本発明の乳化組成物における(G)成分の含有量として、更に好ましくは5~30重量%、特に好ましくは8~30重量%が挙げられる。 In the emulsified composition of the present invention, the content of the component (G) may be appropriately set based on the emulsified form of the emulsion composition, the feeling of use, etc., for example, the total amount of the component (G) is 1 weight. % Or more, preferably 1 to 30% by weight. Further, in the prior art, when an emulsion composition containing the component (A) and the component (B) contains 5% by weight or more, particularly 8% by weight or more, a precipitate or a precipitate is formed. However, in the emulsion composition of the present invention, it is possible to suppress the formation of precipitates and precipitates even when the component (G) is contained in a high content. . In view of the effects of the present invention, the content of the component (G) in the emulsion composition of the present invention is more preferably 5 to 30% by weight, particularly preferably 8 to 30% by weight.
極性油
本発明の乳化組成物は、油相を形成する成分として、極性油を含んでいてもよい。本発明の乳化組成物において、前記無極性油を含む場合には、極性油は含まれていなくてもよく、また前記無極性油と極性油を併用してもよい
Polar oil The emulsified composition of the present invention may contain a polar oil as a component for forming an oil phase. In the emulsion composition of the present invention, when the nonpolar oil is contained, the polar oil may not be contained, and the nonpolar oil and the polar oil may be used in combination.
極性油とは、IOB(無機性/有機性のバランス)が0.05~1.1の範囲にある油分を意味する。極性油としては、薬学的に許容されることを限度として特に制限されないが、例えば、動物油、鉱物油、脂肪酸アルキルエステル、脂肪酸等が挙げられる。 Polar oil means an oil component having an IOB (inorganic / organic balance) in the range of 0.05 to 1.1. The polar oil is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include animal oil, mineral oil, fatty acid alkyl ester, and fatty acid.
植物油としては、具体的には、オリーブ油、小麦胚芽油、こめ油、サフラワー油、大豆油、つばき油、とうもろこし油、なたね油、ごま油、ひまし油、ひまわり油、綿実油、落花生油、ホホバ油、硬化油、アボガド油、ウイキョウ油、チョウジ油、ハッカ油、ユーカリ油、レモン油、オレンジ油、カルナウバロウ、キャンデリラロウ、コメヌカロウ、木ロウ等が挙げられる。これらの植物油は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Examples of vegetable oils include olive oil, wheat germ oil, rice oil, safflower oil, soybean oil, camellia oil, corn oil, rapeseed oil, sesame oil, castor oil, sunflower oil, cottonseed oil, peanut oil, jojoba oil, hydrogenated oil Avocado oil, fennel oil, clove oil, peppermint oil, eucalyptus oil, lemon oil, orange oil, carnauba wax, candelilla wax, rice bran wax, tree wax and the like. These vegetable oils may be used individually by 1 type, and may be used in combination of 2 or more type.
動物油としては、具体的には、ラード、魚油、蜜蝋等が挙げられる。これらの動物油は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Specific examples of animal oils include lard, fish oil, beeswax and the like. These animal oils may be used alone or in combination of two or more.
脂肪酸アルキルエステルとしては、例えば、炭素数4~30の脂肪酸と炭素数1~34のアルコールのエステルが挙げられる。具体的には、トリイソパルミチン酸グリセリル、トリ2-エチルヘキサン酸グリセリル、トリイソオクタン酸グリセリル、ミリスチン酸オクチルドデシル、リンゴ酸ジイソステアリル、ジオクタン酸ネオペンチルグリコール、ジペンタエリトリット脂肪酸エステル、ヒドロキシステアリン酸コレステリルアジピン酸イソプロピル、アジピン酸イソブチル、セバシン酸ジエチル、セバシン酸イソプロピル、セバシン酸ジイソプロピル、エチルヘキサン酸セチル、ミリスチン酸イソプロピル、ミリスチン酸ミリスチル、パルチミン酸イソプロピル、パルチミン酸セチル、オレイン酸エチル、ステアリン酸バチル、イソステアリン酸ヘキシルデシル、リノール酸イソプロピル、トリ(カプリル・カプリン酸)グリセリル、オクタン酸セチル、ステアリン酸ブチル、ラウリン酸ヘキシル、オレイン酸デシル、ジメチルオクタン酸ヘキシルデシル、乳酸セチル、乳酸ミリスチル、酢酸ラノリン、ステアリン酸イソセチル、イソステアリン酸イソセチル、12-ヒドロキシステアリル酸コレステリル、ジ2-エチルヘキサン酸エチレングリコール、ジペンタエリスリトール脂肪酸エステル、モノイソステアリン酸N-アルキルグリコール、ジカプリン酸ネオペンチルグリコール、ジ2-ヘプチルウンデカン酸グリセリン、トリ2-エチルヘキサン酸トリメチロールプロパン、トリイソステアリン酸トリメチロールプロパン、テトラ2-エチルヘキサン酸ペンタエリスリット、トリイソステアリン酸トリメチロールプロパン、セチル2-エチルヘキサノエート、2-エチルヘキシルパルミテート、ナフタリンジカルボン酸ジエチルヘキシル、安息香酸(炭素数12~15)アルキル、セテアリルイソノナノエート、トリ(カプリル酸・カプリン酸)グリセリン、(ジカプリル酸/カプリン酸)ブチレングリコール、トリミリスチン酸グリセリン、トリ2-ヘプチルウンデカン酸グリセライド、ヒマシ油脂肪酸メチルエステル、オレイン酸オレイル、セトステアリルアルコール、アセトグリセライド、パルミチン酸2-ヘプチルウンデシル、N-ラウロイル-L-グルタミン酸-2-オクチルドデシルエステル、アジピン酸ジ2-ヘプチルウンデシル、エチルラウレート、セバシン酸ジ2-エチルヘキシル、ミリスチン酸2-ヘキシルデシル、パルミチン酸2-ヘキシルデシル、アジピン酸2-ヘキシルデシル、コハク酸ジ2-エチルヘキシル等が挙げられる。これらの脂肪酸アルキルエステルは、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Examples of fatty acid alkyl esters include esters of fatty acids having 4 to 30 carbon atoms and alcohols having 1 to 34 carbon atoms. Specifically, glyceryl triisopalmitate, glyceryl tri-2-ethylhexanoate, glyceryl triisooctanoate, octyldodecyl myristate, diisostearyl malate, neopentyl glycol dioctanoate, dipentaerythritol fatty acid ester, hydroxystearin Cholesteryl adipate, isopropyl adipate, isobutyl adipate, diethyl sebacate, isopropyl sebacate, diisopropyl sebacate, cetyl ethylhexanoate, isopropyl myristate, myristyl myristate, isopropyl palmitate, cetyl palmitate, ethyl oleate, butyl stearate , Hexyldecyl isostearate, isopropyl linoleate, glyceryl tri (capryl / caprate), cetyl octoate, steer Butylate, hexyl laurate, decyl oleate, hexyl decyl dimethyloctanoate, cetyl lactate, myristyl lactate, lanolin acetate, isocetyl stearate, isocetyl isostearate, cholesteryl 12-hydroxystearylate, ethylene glycol di-2-ethylhexanoate , Dipentaerythritol fatty acid ester, N-alkyl glycol monoisostearate, neopentyl glycol dicaprate, glycerin di-2-heptylundecanoate, trimethylolpropane tri-2-ethylhexanoate, trimethylolpropane triisostearate, tetra-2-ethyl Hexanoic acid pentaerythritol, triisostearic acid trimethylolpropane, cetyl 2-ethylhexanoate, 2-ethylhexyl palmitate, Diethylhexyl phthalin dicarboxylate, alkyl benzoate (C12-15), cetearyl isononanoate, tri (caprylic / capric) glycerin, (dicaprylic / capric) butylene glycol, glyceryl trimyristate, tri 2-heptylundecanoic acid glyceride, castor oil fatty acid methyl ester, oleic oleate, cetostearyl alcohol, acetoglyceride, 2-heptylundecyl palmitate, N-lauroyl-L-glutamic acid-2-octyldodecyl ester, adipic acid di-2 -Heptylundecyl, ethyl laurate, di-2-ethylhexyl sebacate, 2-hexyldecyl myristate, 2-hexyldecyl palmitate, 2-hexyldecyl adipate, di-2-ethylhexyl succinate And the like. These fatty acid alkyl esters may be used alone or in combination of two or more.
脂肪酸としては、例えば、炭素数4~30の脂肪酸が挙げられ、具体的には、ラウリン酸、ミリスチン酸、パルミチン酸、セバシン酸、オレイン酸、リノール酸等が挙げられる。これらの脂肪酸は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Examples of the fatty acid include fatty acids having 4 to 30 carbon atoms, and specific examples include lauric acid, myristic acid, palmitic acid, sebacic acid, oleic acid, linoleic acid, and the like. These fatty acids may be used alone or in combination of two or more.
これらの極性油の中でも、好ましくは脂肪酸アルキルエステルが挙げられる。 Among these polar oils, fatty acid alkyl esters are preferable.
これらの極性油は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 These polar oils may be used alone or in combination of two or more.
本発明の乳化組成物において、極性油の含有量については、乳化組成物の乳化形態、使用感等を踏まえて適宜設定すればよいが、例えば、0.5~20重量%、好ましくは1~20重量%、更に好ましくは3~15重量%が挙げられる。 In the emulsified composition of the present invention, the polar oil content may be appropriately set in consideration of the emulsified form of the emulsified composition, the feeling of use, etc., for example, 0.5 to 20% by weight, preferably 1 to 20% by weight, more preferably 3 to 15% by weight.
水
本発明の乳化組成物は、水相を形成する基材として水を含有する。
Emulsion composition of the water present invention contains water as a substrate for forming an aqueous phase.
本発明の乳化組成物において、水の含有量については、乳化組成物の乳化形態、使用感等を踏まえて適宜設定すればよいが、例えば、10~90重量%、好ましくは20~85重量%、更に好ましくは30~85重量%が挙げられる。 In the emulsified composition of the present invention, the water content may be appropriately set based on the emulsified form of the emulsified composition, the feeling of use, etc., for example, 10 to 90% by weight, preferably 20 to 85% by weight. More preferred is 30 to 85% by weight.
界面活性剤(ポリオキシエチレン硬化ヒマシ油以外)
本発明の乳化組成物は、乳化状態を安定に形成させるために、前記ポリオキシエチレン硬化ヒマシ油以外の界面活性剤が含まれていてもよい。界面活性剤(ポリオキシエチレン硬化ヒマシ油以外)としては、薬学的に許容されることを限度として特に制限されず、ノニオン性界面活性剤(ポリオキシエチレン硬化ヒマシ油以外)、アニオン性界面活性剤、カチオン性界面活性剤、両性界面活性剤のいずれを使用してもよい。
Surfactant (other than polyoxyethylene hydrogenated castor oil)
The emulsion composition of the present invention may contain a surfactant other than the polyoxyethylene hydrogenated castor oil in order to stably form an emulsified state. The surfactant (other than polyoxyethylene hydrogenated castor oil) is not particularly limited as long as it is pharmaceutically acceptable. Nonionic surfactant (other than polyoxyethylene hydrogenated castor oil), anionic surfactant Any of cationic surfactants and amphoteric surfactants may be used.
ノニオン性界面活性剤(ポリオキシエチレン硬化ヒマシ油以外)としては、具体的には、ポリオキシエチレン(10~50モル)フィトステロールエーテル、ポリオキシエチレン(10~50モル)ジヒドロコレステロールエーテル、ポリオキシエチレン(10~50モル)2-オクチルドデシルエーテル、ポリオキシエチレン(10~50モル)デシルテトラデシルエーテル、ポリオキシエチレン(10~50モル)オレイルエーテル、ポリオキシエチレン(2~50モル)セチルエーテル、ポリオキシエチレン(5~50モル)ベヘニルエーテル、ポリオキシエチレン(5~30モル)ポリオキシプロピレン(5~30モル)2-デシルテトラデシルエーテル、ポリオキシエチレン(10~50モル)ポリオキシプロピレン(2~30モル)セチルエーテル等のポリオキシエチレンアルキルエーテル、これらのリン酸・リン酸塩(ポリオキシエチレンセチルエーテルリン酸ナトリウムなど)、ポリオキシエチレン(20~60モル)ソルビタンモノオレート、ポリオキシエチレン(10~60モル)ソルビタンモノイソステアレート、ポリオキシエチレン(10~80モル)グリセリルモノイソステアレート、ポリオキシエチレン(10~30モル)グリセリルモノステアレート、ポリオキシエチレン(20~100モル)・ポリオキシプロピレン変性シリコーン、ポリオキシエチレン・アルキル変性シリコーン、モノラウリン酸ポリエチレングリコール、モノパルミチン酸ポリエチレングリコール、モノステアリン酸ポリエチレングリコール、ジラウリン酸ポリエチレングリコール、ジパルミチン酸ポリエチレングリコール、ジステアリン酸ポリエチレングリコール、ジオレイン酸ポリエチレングリコール、ジリシノレイン酸ポリエチレングリコール、ポリオキシエチレン硬化ヒマシ油(5~100)、ポリソルベート(20~85)、グリセリン脂肪酸エステル(モノステアリン酸グリセリン等)等が挙げられる。これらのノニオン性界面活性剤(ポリオキシエチレン硬化ヒマシ油以外)は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Specific examples of nonionic surfactants (other than polyoxyethylene hydrogenated castor oil) include polyoxyethylene (10-50 mol) phytosterol ether, polyoxyethylene (10-50 mol) dihydrocholesterol ether, polyoxyethylene (10-50 mol) 2-octyldodecyl ether, polyoxyethylene (10-50 mol) decyl tetradecyl ether, polyoxyethylene (10-50 mol) oleyl ether, polyoxyethylene (2-50 mol) cetyl ether, Polyoxyethylene (5-50 mol) behenyl ether, polyoxyethylene (5-30 mol) polyoxypropylene (5-30 mol) 2-decyltetradecyl ether, polyoxyethylene (10-50 mol) polyoxypropylene ( 2-30 E) Polyoxyethylene alkyl ethers such as cetyl ether, phosphoric acid / phosphates thereof (such as sodium polyoxyethylene cetyl ether phosphate), polyoxyethylene (20 to 60 mol) sorbitan monooleate, polyoxyethylene (10 -60 mol) sorbitan monoisostearate, polyoxyethylene (10-80 mol) glyceryl monoisostearate, polyoxyethylene (10-30 mol) glyceryl monostearate, polyoxyethylene (20-100 mol) poly Oxypropylene-modified silicone, polyoxyethylene / alkyl-modified silicone, polyethylene glycol monolaurate, polyethylene glycol monopalmitate, polyethylene glycol monostearate, polyethylene glycol dilaurate Coal, polyethylene glycol dipalmitate, polyethylene glycol distearate, polyethylene glycol dioleate, polyethylene glycol diricinoleate, polyoxyethylene hydrogenated castor oil (5 to 100), polysorbate (20 to 85), glycerin fatty acid ester (monostearic acid Glycerin and the like). These nonionic surfactants (other than polyoxyethylene hydrogenated castor oil) may be used singly or in combination of two or more.
アニオン性界面活性剤としては、具体的には、ポリオキシエチレンラウリルエーテル硫酸ナトリウム、ラウリル硫酸ナトリウム、ミリスチル硫酸ナトリウム、N-ラウロイルサルコシン酸ナトリウム、N-ミリストリルサルコシン酸ナトリウム、ドデシルベンゼンスルホン酸ナトリウム、水素添加ココナッツ脂肪酸モノグリセリドモノ硫酸ナトリウム、ラウリルスルホ酢酸ナトリウム、α-オレフィンスルホン酸ナトリウム、N-パルミトイルグルタルミン酸ナトリウム、N-メチル-N-アシルタウリンナトリウム等が挙げられる。これらのアニオン性界面活性剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Specific examples of the anionic surfactant include sodium polyoxyethylene lauryl ether sulfate, sodium lauryl sulfate, sodium myristyl sulfate, sodium N-lauroyl sarcosinate, sodium N-myristol sarcosinate, sodium dodecylbenzene sulfonate, Examples include hydrogenated coconut fatty acid monoglyceride sodium monosulfate, sodium lauryl sulfoacetate, sodium α-olefin sulfonate, sodium N-palmitoyl glutarate, sodium N-methyl-N-acyl taurate, and the like. These anionic surfactants may be used individually by 1 type, and may be used in combination of 2 or more type.
カチオン性界面活性剤としては、具体的には、塩化ラウリルトリメチルアンモニウム、塩化ステアリルトリメチルアンモニウム、塩化ベンゼトニウム、塩化ベンザルコニウム、塩化ステアリルジメチルベンジルアンモニウム等が挙げられる。これらのカチオン性界面活性剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 Specific examples of the cationic surfactant include lauryltrimethylammonium chloride, stearyltrimethylammonium chloride, benzethonium chloride, benzalkonium chloride, and stearyldimethylbenzylammonium chloride. These cationic surfactants may be used individually by 1 type, and may be used in combination of 2 or more type.
両性界面活性剤としては、具体的には、ヤシ油脂肪酸アミドプロピルベタイン、ラウリルジメチルアミノ酢酸ベタイン、ラウリルジメチルアミンオキシド、2-アルキル-N-
カルボキシメチル-N-ヒドロキシエチルイミダゾリウムベタイン、N-ラウリルジアミノエチルグリシン、N-ミリスチルジアミノエチルグリシン、N-アルキル-1-ヒドロキシエチルイミダゾリンベタインナトリウム等が挙げられる。これらの両性界面活性剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。
Specific examples of amphoteric surfactants include coconut oil fatty acid amidopropyl betaine, lauryl dimethylaminoacetic acid betaine, lauryl dimethylamine oxide, 2-alkyl-N-
Examples include carboxymethyl-N-hydroxyethyl imidazolium betaine, N-lauryl diaminoethyl glycine, N-myristyl diaminoethyl glycine, N-alkyl-1-hydroxyethyl imidazoline betaine sodium and the like. These amphoteric surfactants may be used alone or in combination of two or more.
これらの界面活性剤の中でも、乳化状態を安定に維持させるという観点から、好ましくはノニオン性界面活性剤(ポリオキシエチレン硬化ヒマシ油以外)が挙げられる。 Among these surfactants, nonionic surfactants (other than polyoxyethylene hydrogenated castor oil) are preferable from the viewpoint of stably maintaining the emulsified state.
これらの界面活性剤は、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 These surfactants may be used alone or in combination of two or more.
本発明の乳化組成物において、界面活性剤(ポリオキシエチレン硬化ヒマシ油以外)の含有量については、界面活性剤の種類、乳化形態等に応じて適宜設定すればよいが、例えば0.5~10重量%、好ましくは1~9重量%、更に好ましくは2~8重量%が挙げられる。 In the emulsified composition of the present invention, the content of the surfactant (other than polyoxyethylene hydrogenated castor oil) may be appropriately set according to the type of surfactant, the emulsified form, etc. 10% by weight, preferably 1 to 9% by weight, more preferably 2 to 8% by weight.
多価アルコール
本発明の乳化組成物は、前述する成分の他に、保湿性等を備えさえるために、必要に応じて、多価アルコールが含まれていてもよい。
Polyhydric alcohol The emulsified composition of the present invention may contain a polyhydric alcohol, if necessary, in addition to the above-described components in order to have moisture retention and the like.
多価アルコールとしては、薬学的に許容されることを限度として特に制限されないが、例えば、エチレングリコール、プロピレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール等が挙げられる。これらの多価アルコールは、1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。 The polyhydric alcohol is not particularly limited as long as it is pharmaceutically acceptable, and examples thereof include ethylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol and the like. These polyhydric alcohols may be used individually by 1 type, and may be used in combination of 2 or more type.
本発明の乳化組成物において、多価アルコールの含有量については、特に制限されないが、例えば0.5~30重量%、好ましくは0.5~25重量%、更に好ましくは1~20重量%が挙げられる。 In the emulsified composition of the present invention, the content of the polyhydric alcohol is not particularly limited. For example, it is 0.5 to 30% by weight, preferably 0.5 to 25% by weight, and more preferably 1 to 20% by weight. Can be mentioned.
増粘剤
本発明の乳化組成物は、前述する成分の他に、所望の粘性等を備えさえるために、必要に応じて、増粘剤が含まれていてもよい。
Thickener The emulsified composition of the present invention may contain a thickener as necessary in order to have a desired viscosity and the like in addition to the components described above.
増粘剤としては、薬学的に許容されることを限度として特に制限されないが、例えば、キサンタンガム、グアーガム、ローカストビーンガム、カラギーナン、デキストラン、メチルセルロース、エチルセルロース、カルボキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、アルギン酸ナトリウム、アルギン酸プロピレングリコールエステル、ポリビニルアルコール、ポリビニルピロリドン、ポリビニルメチルエーテル、カルボキシビニルポリマー、アクリル酸メタクリル酸アルキル共重合体、ポリアクリル酸ナトリウムベントナイト、デキストリン脂肪酸エステル、ペクチン等が挙げられる。これらの増粘剤の中でも、好ましくはキサンタンガム、カルボキシビニルポリマーが挙げられる。これらの増粘剤は1種又は2種以上を組み合わせて使用できる。 The thickener is not particularly limited as long as it is pharmaceutically acceptable.For example, xanthan gum, guar gum, locust bean gum, carrageenan, dextran, methylcellulose, ethylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hydroxyethylcellulose, hydroxypropyl Cellulose, hydroxypropyl methylcellulose, sodium alginate, propylene glycol ester alginate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methyl ether, carboxyvinyl polymer, alkyl methacrylate copolymer, sodium polyacrylate bentonite, dextrin fatty acid ester, pectin, etc. Can be mentioned. Among these thickeners, xanthan gum and carboxyvinyl polymer are preferable. These thickeners can be used alone or in combination of two or more.
本発明の乳化組成物において、増粘剤の含有量については、付与すべき粘性等に応じて適宜設定すればよいが、例えば0.01~5重量%、好ましくは0.1~4重量%、更に好ましくは0.1~3重量%が挙げられる。 In the emulsified composition of the present invention, the content of the thickener may be appropriately set according to the viscosity to be imparted, etc., for example, 0.01 to 5% by weight, preferably 0.1 to 4% by weight. More preferred is 0.1 to 3% by weight.
その他の成分
本発明の乳化組成物は、前述する成分の他に、必要に応じて、皮膚外用剤等に通常使用される他の添加剤が含まれていてもよい。このような添加剤としては、例えば、pH調節剤、緩衝剤、可溶化剤、キレート剤、防腐剤、保存剤、酸化防止剤、安定化剤、キレート剤、香料、着色料等が挙げられる。
Other components In addition to the components described above, the emulsion composition of the present invention may contain other additives usually used for external preparations for skin, etc., if necessary. Examples of such additives include pH adjusters, buffers, solubilizers, chelating agents, preservatives, preservatives, antioxidants, stabilizers, chelating agents, fragrances, and coloring agents.
更に、本発明の乳化組成物は、前述する成分以外の薬効成分が、必要に応じて、含まれていてもよい。このような薬剤としては、例えば、ステロイド剤(デキサメタゾン、塩酸デキサメタゾン、酢酸デキサメタゾン、塩酸ヒドロコルチゾン、吉草酸プレドニゾロン、酢酸プレドニゾロン等)、抗ヒスタミン剤(マレイン酸クロルフェニラミン等)、局所麻酔剤(リドカイン、ジブカイン、プロカイン、テトラカイン、ブピパカイン、メピパカイン、クロロプロカイン、プロパラカイン、メプリルカイン又はこれらの塩、安息香酸アルキルエステル(例えばアミノ安息香酸エチル、塩酸パラブチルアミノ安息香酸ジエチルアミノエチル)、オルソカイン、オキセサゼイン、オキシポリエントキシデカン、ロートエキス、ペルカミンパーゼ、テシットデシチン等)、抗炎症剤(アラントイン、サリチル酸、サリチル酸グリコール、サリチル酸メチル、インドメタシン、フェルビナク、ジクロフェナクナトリウム、ロキソプロフェンナトリウム等)、殺菌剤(塩化ベンザルコニウム、塩化デカリニウム、塩化ベンゼトニウム、塩化セチルピリジニウム、イソプロピルメチルフェノール、塩酸クロルヘキシジン、グルコン酸クロルヘキシジン、アンモニア水、スルファジアジン、乳酸、フェノール等)、鎮痒剤(クロタミトン、チアントール等)、皮膚保護剤(コロジオン、ヒマシ油等)、血行促進成分(ノニル酸ワニリルアミド、ニコチン酸ベンジルエステル、カプサイシン、トウガラシエキス等)、ビタミン類(ビタミンA,B,C,D等)、ムコ多糖類(コンドロイチン硫酸ナトリウム、ヒアルロン酸等)等が挙げられる。 Furthermore, the emulsified composition of the present invention may contain a medicinal component other than the components described above, if necessary. Examples of such drugs include steroid drugs (dexamethasone, dexamethasone hydrochloride, dexamethasone acetate, hydrocortisone hydrochloride, prednisolone valerate, prednisolone acetate, etc.), antihistamines (chlorpheniramine maleate, etc.), local anesthetics (lidocaine, dibucaine, Procaine, tetracaine, bupipacaine, mepipacaine, chloroprocaine, proparacaine, meprilucaine or a salt thereof, alkyl benzoate (for example, ethyl aminobenzoate, diethylaminoethyl parabutylaminobenzoate), orthocaine, oxesazein, oxypolyentoxydecane, Funnel extract, percamin ase, tesit decite, etc.), anti-inflammatory agents (allantoin, salicylic acid, glycol salicylate, methyl salicylate) Indomethacin, felbinac, diclofenac sodium, loxoprofen sodium, etc.), bactericides (benzalkonium chloride, decalinium chloride, benzethonium chloride, cetylpyridinium chloride, isopropylmethylphenol, chlorhexidine hydrochloride, chlorhexidine gluconate, aqueous ammonia, sulfadiazine, lactic acid, phenol, etc. ), Antipruritic agents (crotamiton, thianthol, etc.), skin protectants (collodion, castor oil, etc.), blood circulation promoting ingredients (nonyl acid vanillylamide, nicotinic acid benzyl ester, capsaicin, capsicum extract, etc.), vitamins (vitamins A, B, C, D, etc.), mucopolysaccharide (sodium chondroitin sulfate, hyaluronic acid, etc.) and the like.
乳化状態・製剤形態等
本発明の乳化組成物の乳化状態については、水中油型又は油中水型のいずれであってもよいが、好ましくは水中油型が挙げられる。
The emulsified state of the emulsified composition of the present invention such as emulsified state / form of preparation may be either oil-in-water type or water-in-oil type, preferably oil-in-water type.
本発明の乳化組成物の製剤形態については特に制限されず、例えば、乳液状(乳化系ローション剤)、クリーム状等が挙げられる。 The formulation form of the emulsified composition of the present invention is not particularly limited, and examples thereof include emulsion (emulsion lotion) and cream.
本発明の乳化組成物は、経皮適用される皮膚外用剤として好適に使用される。本発明の乳化組成物として、具体的には、外用医薬品、化粧料、皮膚洗浄料等が挙げられる。これらの製剤形態の中でも、好ましくは外用医薬品が挙げられる。 The emulsified composition of the present invention is suitably used as a skin external preparation applied transdermally. Specific examples of the emulsified composition of the present invention include external medicines, cosmetics, skin cleansing agents and the like. Among these preparation forms, an external medicine is preferable.
製造方法
本発明の乳化組成物は、公知の乳化組成物の製造方法に従って製造することができる。本発明の乳化組成物の製造方法として、例えば、以下に示す方法が挙げられる。先ず、(A)成分、(B)成分、(C)成分、無極性油及び/又は極油、並びに必要に応じて添加される他の親油性成分を混合して油相用組成物を調製する。別途、水、及び必要に応じて添加される他の水溶性成分を混合して水相用組成物を調製する。なお、(E)成分及び/又は界面活性剤((E)成分以外)を含有させる場合には、これらは、油相用組成物又は水相用組成物のいずれか一方又は双方に添加して混合すればよいが、油相用組成物に添加することが好ましい。次いで、得られた油相用組成物と水相用組成物を混合し、ホモジナイザー等の乳化手法によって乳化させることにより、本発明の乳化組成物が製造される。
Production Method The emulsion composition of the present invention can be produced according to a known method for producing an emulsion composition. As a manufacturing method of the emulsion composition of this invention, the method shown below is mentioned, for example. First, (A) component, (B) component, (C) component, nonpolar oil and / or polar oil, and other lipophilic components added as necessary are prepared to prepare an oil phase composition. To do. Separately, water and other water-soluble components added as needed are mixed to prepare an aqueous phase composition. In addition, when (E) component and / or surfactant (other than (E) component) are included, these are added to either or both of the oil phase composition and the aqueous phase composition. What is necessary is just to mix, but adding to the composition for oil phases is preferable. Next, the obtained oil phase composition and aqueous phase composition are mixed and emulsified by an emulsification technique such as a homogenizer to produce the emulsified composition of the present invention.
2.析出物及び沈殿の生成抑制方法
本発明は、更に、(A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(B)ウフェナマートを含む乳化組成物において、析出物及び沈殿の生成を抑制する方法であって、(A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(B)ウフェナマートと共に、(C)ジフェンヒドラミン及び/又はその塩を配合することを特徴とする、析出物及び沈殿の生成抑制方法を提供する。
2. The present invention further relates to an emulsion comprising (A) at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, and (B) ufenamate. In the composition, a method for suppressing the formation of precipitates and precipitates, comprising: (A) at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof; and (B) Provided is a method for suppressing the formation of precipitates and precipitates, which comprises blending (C) diphenhydramine and / or a salt thereof together with ufenamate.
当該方法において、使用する(A)~(C)の種類や含有量、配合される他の成分の種類や含有量、乳化によって製される乳化組成物の製剤形態等については、前記「1.乳化組成物」の場合と同様である。 In the method, the types and contents of (A) to (C) to be used, the types and contents of other components to be blended, the formulation form of an emulsified composition produced by emulsification, and the like are described in “1. The same as in the case of the “emulsified composition”.
3.析出物及び沈殿の生成、並びに油相と水相の相分離の抑制方法
本発明は、更に、(A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(B)ウフェナマートを含む乳化組成物において、析出物及び沈殿の生成、並びに油相と水相の相分離を抑制する方法であって、(A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(B)ウフェナマートと共に、(C)ジフェンヒドラミン及び/又はその塩、並びに(D)25℃で固体の高級アルコールを配合することを特徴とする、析出物及び沈殿の生成、並びに油相と水相の相分離の抑制方法を提供する。
3. The present invention further includes (A) glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof selected from the group consisting of a precipitate and a precipitate, and a method for suppressing phase separation between an oil phase and an aqueous phase. In the emulsion composition containing 1 type and (B) Ufenamate, it is a method for suppressing the formation of precipitates and precipitates, and the phase separation of the oil phase and the aqueous phase, comprising (A) glycyrrhetinic acid, glycyrrhizic acid, (C) diphenhydramine and / or a salt thereof, and (D) a higher alcohol that is solid at 25 ° C., together with at least one selected from the group consisting of derivatives, and salts thereof, and (B) ufenamate. The present invention provides a method for suppressing the formation of precipitates and precipitates, and the phase separation of an oil phase and an aqueous phase.
当該方法において、使用する(A)~(D)の種類や含有量、配合される他の成分の種類や含有量、乳化によって製される乳化組成物の製剤形態等については、前記「1.乳化組成物」の場合と同様である。 In the method, the types and contents of (A) to (D) to be used, the types and contents of other components to be blended, the formulation form of the emulsified composition produced by emulsification, etc. are described in “1. The same as in the case of the “emulsified composition”.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 Hereinafter, the present invention will be described more specifically with reference to examples. However, the present invention is not limited to these examples.
試験例
表1に示す組成のクリーム状の水中油型乳化組成物を製造し、沈殿生成の程度、析出物の生成の程度、及び相分離の程度について、評価した。クリーム状の水中油型乳化組成物の製造方法、及び試験方法は、以下の通りである。
Test Example A creamy oil-in-water emulsion composition having the composition shown in Table 1 was produced and evaluated for the degree of precipitation, the degree of precipitation, and the degree of phase separation. The production method and test method of the creamy oil-in-water emulsion composition are as follows.
[クリーム状の水中油型乳化組成物の製造方法]
まず、表1中の(I)に示す成分の内、(A)成分(グリチルレチン酸又はグリチルリチン酸ジカリウム)以外の成分を所定量計り取り、80℃に加温して混合した。その後、(A)成分を所定量添加して混合し、油相用組成物を調製した。別途、表1中の(II)に示す成分を所定量計り取り、混合して水相用組成物を調製した。水相用組成物を80℃に加温した後に、80℃の油相用組成物を少量ずつ添加し、混合しながら乳化を行った。その後、30℃まで冷却し、クリーム状の水中油型乳化組成物を得た。
[Method for producing creamy oil-in-water emulsion composition]
First, among the components shown in (I) of Table 1, a predetermined amount of components other than the component (A) (glycyrrhetinic acid or dipotassium glycyrrhizinate) was weighed and heated to 80 ° C. and mixed. Thereafter, a predetermined amount of component (A) was added and mixed to prepare an oil phase composition. Separately, a predetermined amount of the component shown in (II) of Table 1 was weighed and mixed to prepare an aqueous phase composition. After the water phase composition was heated to 80 ° C., the 80 ° C. oil phase composition was added in small portions and emulsified while mixing. Then, it cooled to 30 degreeC and obtained the cream-like oil-in-water emulsion composition.
[試験方法]
(沈殿生成の程度)
各乳化組成物の製造工程において調製した油相用組成物について、調製直後の外観を目視にて観察し、以下の判定基準に従って、沈殿生成の程度を評価した。
<沈殿生成の程度の判定基準>
◎ :液が澄明であり、沈殿が一切認められない。
○ :液が澄明であるが、沈殿が僅かに生じている。
× :液が懸濁しており、沈殿が一部認められる。
××:液が懸濁しており、沈殿が著しく認められる。
[Test method]
(Degree of precipitation)
About the oil phase composition prepared in the manufacturing process of each emulsified composition, the appearance immediately after the preparation was visually observed, and the degree of precipitation was evaluated according to the following criteria.
<Criteria for the degree of precipitation formation>
A: The liquid is clear and no precipitation is observed.
○: The liquid is clear, but slight precipitation occurs.
X: The liquid is suspended and some precipitation is observed.
XX: The liquid is suspended and precipitation is remarkably observed.
(析出物の生成の程度)
各乳化組成物を1日間室温で保存した後に、偏光顕微鏡にて観察し、以下の判定基準に従って、析出物の生成の程度を評価した。
<析出物の生成の程度の判定基準>
◎ :析出物が一切認められない。
○ :微細な析出物が僅かに認められるが、問題になるような析出物は認められない。
× :大きな析出物はあまりないが、析出物が多数認められる。
××:大きな析出物が多数認められる。
(Degree of precipitate formation)
Each emulsion composition was stored for 1 day at room temperature, then observed with a polarizing microscope, and the degree of precipitate formation was evaluated according to the following criteria.
<Criteria for the degree of precipitate formation>
A: No precipitate is observed at all.
○: Slight fine precipitates are observed, but no problematic precipitates are observed.
X: There are not many large precipitates, but many precipitates are observed.
XX: Many large precipitates are observed.
(相分離の程度)
各乳化組成物を40℃で3カ月間及び50℃で1カ月間保存した後に、外観を観察し、以下の判定基準に従って、相分離の程度を評価した。なお、比較例1~8の乳化組成物では、沈殿及び析出物の生成が認められたため、相分離の程度の評価は行わなかった。
<相分離の程度の判定基準>
◎:40℃で3カ月間及び50℃で1カ月間の双方の条件で油相と水相の相分離が全く認められない。
○:40℃3ヶ月間及び50℃で1カ月間の双方の条件で油相と水相の相分離は殆ど認められない。
△:40℃で3カ月間の条件で油相と水相の相分離は殆ど認められない。但し、50℃で1カ月間の条件で油相と水相の相分離が明らかに認められる。
×:40℃で3カ月間又は50℃で1カ月間の条件で油相と水相の相分離が明らかに認められる。
(Degree of phase separation)
After each emulsion composition was stored at 40 ° C. for 3 months and at 50 ° C. for 1 month, the appearance was observed, and the degree of phase separation was evaluated according to the following criteria. In the emulsified compositions of Comparative Examples 1 to 8, precipitation and formation of precipitates were observed, and thus the degree of phase separation was not evaluated.
<Criteria for the degree of phase separation>
(Double-circle): The phase separation of an oil phase and a water phase is not recognized at all on both conditions for 3 months at 40 degreeC and for 1 month at 50 degreeC.
○: Almost no phase separation between the oil phase and the aqueous phase is observed under both conditions of 40 ° C. for 3 months and 50 ° C. for 1 month.
(Triangle | delta): The phase separation of an oil phase and a water phase is hardly recognized on the conditions for 3 months at 40 degreeC. However, the phase separation of the oil phase and the water phase is clearly observed at 50 ° C. for one month.
X: Phase separation of the oil phase and the aqueous phase is clearly observed under conditions of 3 months at 40 ° C. or 1 month at 50 ° C.
[試験結果]
得られた結果を表1に示す。グリチルレチン酸及びウフェナマートを含み、ジフェンヒドラミンを含まない乳化組成物では、沈殿及び析出物の生成が認められた(比較例1~8)。また、グリチルレチン酸とウフェナマート共に無極性油を含み、ジフェンヒドラミンを含まない乳化組成物では、沈殿及び析出物の生成が顕著になる傾向が認められた(比較例2~8)。
[Test results]
The obtained results are shown in Table 1. In the emulsion composition containing glycyrrhetinic acid and ufenamate and not containing diphenhydramine, precipitation and formation of precipitates were observed (Comparative Examples 1 to 8). In addition, in the emulsion composition containing both non-polar oil and not containing diphenhydramine, both glycyrrhetinic acid and ufenamate tended to show significant precipitation and precipitate formation (Comparative Examples 2 to 8).
これに対して、グリチルレチン酸又はグリチルリチン酸ジカリウムと、ウフェナマートと、ジフェンヒドラミンを含む乳化組成物では、沈殿及び析出物の生成を抑制できていた(実施例1~14)。また、これらの成分に加えて、25℃で固体の高級アルコールを含む乳化組成物では、沈殿及び析出物の生成の抑制効果が向上していた(実施例2~14)。 On the other hand, in the emulsion composition containing glycyrrhetinic acid or dipotassium glycyrrhizinate, ufenamate, and diphenhydramine, the formation of precipitates and precipitates could be suppressed (Examples 1 to 14). In addition to these components, an emulsion composition containing a higher alcohol that is solid at 25 ° C. has improved the effect of suppressing precipitation and precipitate formation (Examples 2 to 14).
また、グリチルレチン酸又はグリチルリチン酸ジカリウムと、ウフェナマートと、ジフェンヒドラミンに加えて、ポリオキシエチレン硬化ヒマシ油を含む乳化組成物では、油相と水相の相分離も抑制できていた(実施例7~14)。更に、これらの成分に加えてウールワックスアルコールを含む乳化組成物では、油相と水相の相分離の抑制効果が更に向上していた(実施例12及び13)。 Further, in the emulsion composition containing polyoxyethylene hydrogenated castor oil in addition to glycyrrhetinic acid or dipotassium glycyrrhizinate, ufenamate, and diphenhydramine, phase separation between the oil phase and the aqueous phase could be suppressed (Examples 7 to 14). ). Furthermore, in the emulsion composition containing wool wax alcohol in addition to these components, the effect of suppressing the phase separation between the oil phase and the aqueous phase was further improved (Examples 12 and 13).
処方例
表2に示す組成の水中油型乳化組成物を調製した。これらの製剤は、いずれも、前記試験例の場合と同様に、沈殿及び析出物の生成が抑制された乳化組成物である。
Formulation Example An oil-in-water emulsion composition having the composition shown in Table 2 was prepared. Each of these preparations is an emulsified composition in which the formation of precipitates and precipitates is suppressed as in the case of the test example.
Claims (9)
(A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(A)ウフェナマートと共に、(C)ジフェンヒドラミン及び/又はその塩を配合する、方法。 (A) At least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, and (B) a method for suppressing the formation of precipitates and precipitates in an emulsified composition containing ufenamate Because
A method of blending (C) diphenhydramine and / or a salt thereof with (A) at least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, and (A) ufenamate.
(A)グリチルレチン酸、グリチルリチン酸、これらの誘導体、及びこれらの塩よりなる群から選択される少なくとも1種、並びに(B)ウフェナマートと共に、(C)ジフェンヒドラミン及び/又はその塩、並びに(D)25℃で固体の高級アルコールを配合する、方法。 (A) At least one selected from the group consisting of glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and salts thereof, and (B) formation of precipitates and precipitates, and an oil phase in an emulsion composition containing ufenamate A method of suppressing phase separation between the water phase and the water phase,
(A) glycyrrhetinic acid, glycyrrhizic acid, derivatives thereof, and at least one selected from the group consisting of these salts, and (B) ufenamate, (C) diphenhydramine and / or a salt thereof, and (D) 25 A method of blending a higher alcohol that is solid at ℃.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017-101825 | 2017-05-23 | ||
| JP2017101825A JP7170383B2 (en) | 2017-05-23 | 2017-05-23 | emulsion composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2018216659A1 true WO2018216659A1 (en) | 2018-11-29 |
| WO2018216659A8 WO2018216659A8 (en) | 2020-10-01 |
Family
ID=64396810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2018/019511 Ceased WO2018216659A1 (en) | 2017-05-23 | 2018-05-21 | Emulsion composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP7170383B2 (en) |
| TW (1) | TWI806867B (en) |
| WO (1) | WO2018216659A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7271163B2 (en) * | 2018-12-21 | 2023-05-11 | 小林製薬株式会社 | external composition |
| JP7584886B2 (en) * | 2018-12-21 | 2024-11-18 | 小林製薬株式会社 | Emulsion composition |
| CN114173757B (en) * | 2019-08-09 | 2024-10-29 | 丸善制药株式会社 | Composition containing glycyrrhetinic acid derivative |
| JP7709825B2 (en) * | 2020-10-21 | 2025-07-17 | 小林製薬株式会社 | External composition |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003321347A (en) * | 2002-05-07 | 2003-11-11 | Rohto Pharmaceut Co Ltd | Gel ointment |
| JP2010248169A (en) * | 2009-03-27 | 2010-11-04 | Shiseido Co Ltd | Water-in-oil type emulsion skin lotion |
| JP2012136491A (en) * | 2010-12-28 | 2012-07-19 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2012224550A (en) * | 2011-04-15 | 2012-11-15 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2017088512A (en) * | 2015-11-05 | 2017-05-25 | 小林製薬株式会社 | Emulsified composition |
-
2017
- 2017-05-23 JP JP2017101825A patent/JP7170383B2/en active Active
-
2018
- 2018-05-18 TW TW107116928A patent/TWI806867B/en active
- 2018-05-21 WO PCT/JP2018/019511 patent/WO2018216659A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003321347A (en) * | 2002-05-07 | 2003-11-11 | Rohto Pharmaceut Co Ltd | Gel ointment |
| JP2010248169A (en) * | 2009-03-27 | 2010-11-04 | Shiseido Co Ltd | Water-in-oil type emulsion skin lotion |
| JP2012136491A (en) * | 2010-12-28 | 2012-07-19 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2012224550A (en) * | 2011-04-15 | 2012-11-15 | Shiseido Co Ltd | Ufenamate-containing skin care preparation |
| JP2017088512A (en) * | 2015-11-05 | 2017-05-25 | 小林製薬株式会社 | Emulsified composition |
Non-Patent Citations (3)
| Title |
|---|
| MORI, HIROSHI ET AL.: "Effect of Topical Application of Epiamart S on Immediate-Type Anaphylaxis and Delayed-Type Hypersensitivity", JAPANESE PHARMACOLOGY & THERAPEUTICS, vol. 24, no. 10, 1996, pages 97 - 101, ISSN: 0386-3603 * |
| NAKASHIMA, MASAYA ET AL.: "EAntihistaminic and Anti-Inflammatory Effects of Epiamart S by Topical Application", JAPANESE PHARMACOLOGY & THERAPEUTICS, vol. 24, no. 10, 1996, pages 91 - 95, ISSN: 0386-3603 * |
| SHISEIDO CO., LTD.,: "Encron UF Cream EX", UFC-EX 12094, September 2012 (2012-09-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018197201A (en) | 2018-12-13 |
| TWI806867B (en) | 2023-07-01 |
| TW201906598A (en) | 2019-02-16 |
| JP7170383B2 (en) | 2022-11-14 |
| WO2018216659A8 (en) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7170384B2 (en) | emulsion composition | |
| JP7170385B2 (en) | emulsion composition | |
| RU2568598C2 (en) | Pharmaceutical formulations containing corticosteroids for topical application | |
| JP6903410B2 (en) | Oil-in-water emulsified composition | |
| WO2018216659A1 (en) | Emulsion composition | |
| JP6632837B2 (en) | Emulsion composition | |
| JP7048283B2 (en) | Skin darkening improver | |
| JP6967369B2 (en) | Emulsifying composition | |
| JP6495706B2 (en) | Skin external composition | |
| JP7312527B2 (en) | emulsion composition | |
| JP5300038B2 (en) | Topical skin preparation | |
| JP5912238B2 (en) | Emulsified composition | |
| JP7048282B2 (en) | External composition for skin | |
| JP2019048890A (en) | Foamy pharmaceutical composition for external use | |
| JP4521899B2 (en) | Clotamiton-containing skin external solution | |
| JP2022097835A (en) | Oil-in-water emulsion composition | |
| JP2020105091A (en) | External emulsion composition | |
| TW202417003A (en) | Composition for external preparation for skin | |
| WO2020137683A1 (en) | Composition for external use | |
| JP2023090338A (en) | emulsion composition | |
| JP6537775B2 (en) | Emulsified composition | |
| WO2008038806A1 (en) | Antipruritic agent | |
| JP2023065336A (en) | Oil-in-water emulsion composition | |
| JP2025095431A (en) | External composition | |
| WO2021046444A1 (en) | Topical compositions comprising a corticosteroid for the treatment of psoriasis in pediatric patients |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18805138 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| ENP | Entry into the national phase |
Ref document number: 2019520245 Country of ref document: JP Kind code of ref document: A |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 18805138 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |